The present disclosure pertains to medical devices, and methods for manufacturing medical devices. More particularly, the present disclosure pertains to medical devices and methods for treatment of hypertension.
A wide variety of intracorporeal medical devices have been developed for medical use, for example, intravascular use. Some of these devices include guidewires, catheters, and the like. These devices are manufactured by any one of a variety of different manufacturing methods and may be used according to any one of a variety of methods. Of the known medical devices and methods, each has certain advantages and disadvantages. There is an ongoing need to provide alternative medical devices as well as alternative methods for manufacturing and using medical devices.
This disclosure provides design, material, manufacturing method, and use alternatives for medical devices. An example medical device for renal nerve ablation may include a catheter shaft having a distal region. An expandable balloon may be coupled to the distal region. An electrode assembly may be coupled to the balloon. The electrode assembly may include a first electrode pad including one or more electrodes. The first electrode pad may have a first lead-in edge, a first protruding edge, and a first transition region with a continuously changing curvature disposed between the first lead-in edge and the first protruding edge.
Another example medical device for renal nerve ablation may include a catheter shaft having a distal region. An expandable balloon may be coupled to the distal region. An electrode assembly may be attached to an outer surface of the balloon. The electrode assembly may include a first electrode pad including a first pair of bipolar electrodes and a second electrode pad having a second pair of bipolar electrodes. The first electrode pad may have a first lead-in edge, a first protruding edge, and a first transition region with a first continuously changing curvature disposed between the first lead-in edge and the first protruding edge. The second electrode pad may have a second lead-in edge, a second protruding edge, and a second transition region with a second continuously changing curvature disposed between the second lead-in edge and the second protruding edge.
Another example medical device for renal nerve ablation may include a catheter shaft having a distal region. An expandable balloon may be coupled to the distal region. An electrode assembly may be attached to an outer surface of the balloon. The electrode assembly may include a first electrode pad including a first pair of bipolar electrodes and a second electrode pad having a second pair of bipolar electrodes. The first electrode pad may have a first lead-in edge, a first protruding edge, and a first transition region with a first continuously changing curvature disposed between the first lead-in edge and the first protruding edge. The first continuously changing curvature may be defined by a first mathematically continuous function. The second electrode pad may have a second lead-in edge, a second protruding edge, and a second transition region with a second continuously changing curvature disposed between the second lead-in edge and the second protruding edge. The second continuously changing curvature may be defined by a second mathematically continuous function.
The above summary of some embodiments is not intended to describe each disclosed embodiment or every implementation of the present disclosure. The Figures, and Detailed Description, which follow, more particularly exemplify these embodiments.
For the following defined terms, these definitions shall be applied, unless a different definition is given in the claims or elsewhere in this specification.
All numeric values are herein assumed to be modified by the term “about,” whether or not explicitly indicated. The term “about” generally refers to a range of numbers that one of skill in the art would consider equivalent to the recited value (i.e., having the same function or result). In many instances, the terms “about” may include numbers that are rounded to the nearest significant figure.
The recitation of numerical ranges by endpoints includes all numbers within that range (e.g. 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5).
As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the content clearly dictates otherwise. As used in this specification and the appended claims, the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise.
It is noted that references in the specification to “an embodiment”, “some embodiments”, “other embodiments”, etc., indicate that the embodiment described may include one or more particular features, structures, and/or characteristics. However, such recitations do not necessarily mean that all embodiments include the particular features, structures, and/or characteristics. Additionally, when particular features, structures, and/or characteristics are described in connection with one embodiment, it should be understood that such features, structures, and/or characteristics may also be used connection with other embodiments whether or not explicitly described unless clearly stated to the contrary.
The following detailed description should be read with reference to the drawings in which similar elements in different drawings are numbered the same. The drawings, which are not necessarily to scale, depict illustrative embodiments and are not intended to limit the scope of the invention.
Physicians use catheters to gain access to and affect therapies by altering interior tissues of the body, particularly within or about the lumens of the body such as blood vessels. For example, balloon angioplasty and other catheters often are used to open arteries that have been narrowed due to atherosclerotic disease.
Catheters can be used to perform renal denervation by RF energy treatment in patients with refractory hypertension. This is a relatively new procedure, which has been found to be clinically effective in treating hypertension. In the procedure, RF energy is applied to walls of the renal artery to reduce hyper-activation (which is often the cause of chronic hypertension) of the sympathetic nervous system adjacent to the renal artery. This procedure has been found to be successful in some cases, but also is associated with a significant amount of pain, and existing treatments can be both relatively difficult for the physician to accurately perform and quite time-consuming.
Another condition affecting many patients is Congestive Heart Failure (“CHF”). CHF is a condition which occurs when the heart becomes damaged and blood flow is reduced to the organs of the body. If blood flow decreases sufficiently, kidney function becomes altered, which results in fluid retention, abnormal hormone secretions and increased constriction of blood vessels. These results increase the workload of the heart and further decrease the capacity of the heart to pump blood through the kidneys and circulatory system.
It is believed that progressively decreasing perfusion of the kidneys is a principal non-cardiac cause perpetuating the downward spiral of CHF. For example, as the heart struggles to pump blood, the cardiac output is maintained or decreased and the kidneys conserve fluid and electrolytes to maintain the stroke volume of the heart. The resulting increase in pressure further overloads the cardiac muscle such that the cardiac muscle has to work harder to pump against a higher pressure. The already damaged cardiac muscle is then further stressed and damaged by the increased pressure. In addition to exacerbating heart failure, kidney failure can lead to a downward spiral and further worsening kidney function. For example, in the forward flow heart failure described above, (systolic heart failure) the kidney becomes ischemic. In backward heart failure (diastolic heart failure), the kidneys become congested vis-a-vis renal vein hypertension. Therefore, the kidney can contribute to its own worsening failure.
The functions of the kidneys can be summarized under three broad categories: filtering blood and excreting waste products generated by the body's metabolism; regulating salt, water, electrolyte and acid-base balance; and secreting hormones to maintain vital organ blood flow. Without properly functioning kidneys, a patient will suffer water retention, reduced urine flow and an accumulation of waste toxins in the blood and body. These conditions result from reduced renal function or renal failure (kidney failure) and are believed to increase the workload of the heart. In a CHF patient, renal failure will cause the heart to further deteriorate as fluids are retained and blood toxins accumulate due to the poorly functioning kidneys. The resulting hypertension also has dramatic influence on the progression of cerebrovascular disease and stroke.
The autonomic nervous system is a network of nerves that affect almost every organ and physiologic system to a variable degree. Generally, the system is composed of sympathetic and parasympathetic nerves. For example, the sympathetic nerves to the kidney traverse the sympathetic chain along the spine and synapse within the ganglia of the chain or within the celiac ganglia, then proceeding to innervate the kidney via post-ganglionic fibers inside the “renal nerves”. Within the renal nerves, which travel along the renal hila (artery and to some extent the vein), are the post-ganglionic sympathetic nerves and the afferent nerves from the kidney. The afferent nerves from the kidney travel within the dorsal root (if they are pain fibers) and into the anterior root if they are sensory fibers, then into the spinal cord and ultimately to specialized regions of the brain. The afferent nerves, baroreceptors and chemoreceptors, deliver information from the kidneys back to the sympathetic nervous system via the brain; their ablation or inhibition is at least partially responsible for the improvement seen in blood pressure after renal nerve ablation, or denervation, or partial disruption. It has also been suggested and partially proven experimentally that the baroreceptor response at the level of the carotid sinus is mediated by the renal artery afferent nerves such that loss of the renal artery afferent nerve response blunts the response of the carotid baroreceptors to changes in arterial blood pressure (American J. Physiology and Renal Physiology 279:F491-F501, 2000, the disclosure of which is incorporated herein by reference).
It has been established in animal models that the heart failure condition results in abnormally high sympathetic activation of the kidneys. An increase in renal sympathetic nerve activity leads to decreased removal of water and sodium from the body, as well as increased renin secretion which stimulates aldosterone secretion from the adrenal gland. Increased renin secretion can lead to an increase in angiotensin II levels, which leads to vasoconstriction of blood vessels supplying the kidneys as well as systemic vasoconstriction, all of which lead to a decrease in renal blood flow and hypertension. Reduction in sympathetic renal nerve activity, e.g., via de-innervation, may reverse these processes and in fact has been shown to in the clinic.
As with hypertension, sympathetic nerve overdrive contributes to the development and progression of CHF. Norepinephrine spillover from the kidney and heart to the venous plasma is even higher in CHF patients compared to those with essential hypertension. Chronic sympathetic nerve stimulation overworks the heart, both directly as the heart increases its output and indirectly as a constricted vasculature presents a higher resistance for the heart to pump against. As the heart strains to pump more blood, left ventricular mass increases and cardiac remodeling occurs. Cardiac remodeling results in a heterogeneous sympathetic activation of the heart which further disrupts the synchrony of the heart contraction. Thus, remodeling initially helps increase the pumping of the heart but ultimately diminishes the efficiency of the heart. Decrease in function of the left ventricle further activates the sympathetic nervous system and the renin-angiotensin-aldosterone system, driving the vicious cycle that leads from hypertension to CHF.
Embodiments of the present disclosure relate to a power generating and control apparatus, often for the treatment of targeted tissue in order to achieve a therapeutic effect. In some embodiments, the target tissue is tissue containing or proximate to nerves, including renal arteries and associated renal nerves. In other embodiments the target tissue is luminal tissue, which may further comprise diseased tissue such as that found in arterial disease.
In yet another exemplary embodiment of the present disclosure, the ability to deliver energy in a targeted dosage may be used for nerve tissue in order to achieve beneficial biologic responses. For example, chronic pain, urologic dysfunction, hypertension, and a wide variety of other persistent conditions are known to be affected through the operation of nervous tissue. For example, it is known that chronic hypertension that may not be responsive to medication may be improved or eliminated by disabling excessive nerve activity proximate to the renal arteries. It is also known that nervous tissue does not naturally possess regenerative characteristics. Therefore it may be possible to beneficially affect excessive nerve activity by disrupting the conductive pathway of the nervous tissue. When disrupting nerve conductive pathways, it is particularly advantageous to avoid damage to neighboring nerves or organ tissue. The ability to direct and control energy dosage is well-suited to the treatment of nerve tissue. Whether in a heating or ablating energy dosage, the precise control of energy delivery as described and disclosed herein may be directed to the nerve tissue. Moreover, directed application of energy may suffice to target a nerve without the need to be in exact contact, as would be required when using a typical ablation probe. For example, eccentric heating may be applied at a temperature high enough to denature nerve tissue without causing ablation and without requiring the piercing of luminal tissue. However, it may also be desirable to configure the energy delivery surface of the present disclosure to pierce tissue and deliver ablating energy similar to an ablation probe with the exact energy dosage being controlled by a power control and generation apparatus.
In some embodiments, efficacy of the denervation treatment can be assessed by measurement before, during, and/or after the treatment to tailor one or more parameters of the treatment to the particular patient or to identify the need for additional treatments. For instance, a denervation system may include functionality for assessing whether a treatment has caused or is causing a reduction in neural activity in a target or proximate tissue, which may provide feedback for adjusting parameters of the treatment or indicate the necessity for additional treatments.
While the disclosure focuses on the use of the technology in the vasculature, the technology would also be useful for other luminal tissues. Other anatomical structures in which the present disclosure may be used are the esophagus, the oral cavity, the nasopharyngeal cavity, the auditory tube and tympanic cavity, the sinus of the brain, the arterial system, the venous system, the heart, the larynx, the trachea, the bronchus, the stomach, the duodenum, the ileum, the colon, the rectum, the bladder, the ureter, the ejaculatory duct, the vas deferens, the urethra, the uterine cavity, the vaginal canal, and the cervical canal.
System Overview
In some embodiments, the control unit 110 may include a processor or otherwise be coupled to a processor to control or record treatment. The processor will typically comprise computer hardware and/or software, often including one or more programmable processor units running machine readable program instructions or code for implementing some, or all, of one or more of the embodiments and methods described herein. The code will often be embodied in a tangible media such as a memory (optionally a read only memory, a random access memory, a non-volatile memory, or the like) and/or a recording media (such as a floppy disk, a hard drive, a CD, a DVD, a non-volatile solid-state memory card, or the like). The code and/or associated data and signals may also be transmitted to or from the processor via a network connection (such as a wireless network, an ethernet, an internet, an intranet, or the like), and some or all of the code may also be transmitted between components of a catheter system and within the processor via one or more buses, and appropriate standard or proprietary communications cards, connectors, cables, and the like will often be included in the processor. The processor may often be configured to perform the calculations and signal transmission steps described herein at least in part by programming the processor with the software code, which may be written as a single program, a series of separate subroutines or related programs, or the like. The processor may comprise standard or proprietary digital and/or analog signal processing hardware, software, and/or firmware, and may desirable have sufficient processing power to perform the calculations described herein during treatment of the patient, the processor optionally comprising a personal computer, a notebook computer, a tablet computer, a proprietary processing unit, or a combination thereof. Standard or proprietary input devices (such as a mouse, keyboard, touchscreen, joystick, etc.) and output devices (such as a printer, speakers, display, etc.) associated with modern computer systems may also be included, and processors having a plurality of processing units (or even separate computers) may be employed in a wide range of centralized or distributed data processing architectures.
In some embodiments, control software for the system 100 may use a client-server schema to further enhance system ease of use, flexibility, and reliability. “Clients” are the system control logic; “servers” are the control hardware. A communications manager delivers changes in system conditions to subscribing clients and servers. Clients “know” what the present system condition is, and what command or decision to perform based on a specific change in condition. Servers perform the system function based on client commands. Because the communications manager is a centralized information manager, new system hardware may not require changes to prior existing client-server relationships; new system hardware and its related control logic may then merely become an additional “subscriber” to information managed through the communications manager. This control schema may provide the benefit of having a robust central operating program with base routines that are fixed; no change to base routines may be necessary in order to operate new circuit components designed to operate with the system.
Expandable Device and Electrode Assemblies
Returning to
As shown in
The treatment zones A-D and associated electrode assemblies 140a-d are further illustrated in
a. Overlapping and Non-Overlapping Treatment Zones
Returning to
In other embodiments, however, the energy applied by the electrode assemblies, such as the electrode assemblies shown in
Whether or not treatment zones between electrodes/electrode pairs will overlap may be influenced by a wide variety of factors, including, but not limited to, electrode geometry, electrode placement density, electrode positioning, ground/common electrode(s) placement and geometry (in monopolar embodiments), energy generator output settings, output voltage, output power, duty cycle, output frequency, tissue characteristics, tissue type, etc.
In some embodiments, individual electrodes of a bipolar electrode pair may each define its own treatment zone, and such treatment zones may partially or entirely overlap.
In
It has been experimentally determined that at least some electrosurgical systems utilizing an array of balloon-mounted electrodes can create overlapping treatment zones between adjacent electrode pads, and, in at least some instances, create treatment zones that are effectively substantially continuous about a circumference of a body passageway. In one experiment, a catheter and expandable balloon similar to that shown and described in U.S. Pub. No. 2008/0188912 (incorporated in its entirety by this reference), particularly at
In one experiment utilizing a catheter-based balloon electrode array similar to that of
Kidneys and renal arteries were explanted intact with underlying muscle and fixed in 10% neutral buffered formalin. Fixed tissues were then submitted for histopathological processing and evaluation. Each vessel was trimmed at approximately every 3-4 mm until the tissue was exhausted, processed, embedded in paraffin, sectioned twice at ˜5 microns, and stained with hematoxylin and eosin (H+E) and elastin trichrome (ET). Kidneys were trimmed at three levels (cranial, center and caudal), processed, embedded in paraffin, sectioned and stained with H+E. All resulting slides were examined via light microscopy.
Evaluation of step sections from six acute arteries treated at various power and duration of radio-frequency regimens or left untreated, and evaluation of dependent kidneys showed acute thermal changes characterized by coagulation necrosis in the media and perivascular tissues and collagen hyalinization.
b. Electrode Assembly Structure
Returning to
The electrode assembly 200 shown in
The distal electrode pad 208 includes a plurality of discrete traces layered on top of the base layer 202. These traces include a ground trace 210, an active electrode trace 212, and a sensor trace 214. The ground trace 210 includes an elongated electrode support 216 laterally offset from a sensor ground pad 218. The sensor ground pad 218 is electrically coupled to the elongated support 216 of the ground trace 210 and is centrally located on the distal electrode pad 208. A bridge 220 connects a distal most portion of the sensor ground pad 218 to a distal portion of the elongated electrode support 216 of the ground trace 210. The bridge 220 tapers down in width as it travels to the sensor ground pad 218. In some embodiments, the bridge 220 has a relatively uniform and thin width to enable a desired amount of flexibility. The elongated electrode support 216 tapers down in width at its proximal end, however, this is not required. In some embodiments, the elongated electrode support 216 can abruptly transition to a much thinner trace at its proximal portion, to enable a desired amount of flexibility. Generally, the curvature of the traces where necking is shown is optimized to reduce balloon recapture forces and the potential for any snagging that sharper contours may present. The shape and position of the traces are also optimized to provide dimensional stability to the electrode assembly 200 as a whole, so as to prevent distortion during deployment and use.
In some instances, the distal electrode pad 208, the proximal electrode pad 236, or both may be configured to reduce recapture forces, reduce snagging between the electrode assembly 200 and a lumen through which the electrode assembly 200 may travel when the medical device is being withdrawn therethrough, increase the ability of the balloon to more easily fold and/or refold after use, and/or reduce delamination of the electrode assembly 200 from the balloon or other medical device to which it is attached during withdrawal through a lumen including the lumen of a catheter (e.g., a guide catheter), introducer, or sheath. Illustratively, after an electronic assembly 200 that is adhered to a balloon portion of a balloon catheter to form a composite structure has been used for its intended purpose, the composite structure may fold onto itself in various shapes (e.g., a pancake shape, an S-shape, etc.) along the axial direction and withdrawn through a lumen of a catheter. During the withdrawal of the composite structure, the electronic assembly 200 may interact with the lumen at transition points, for example, along the edges of the pads 208/236 and such interactions may cause abrupt changes in the force required to withdraw the composite structure through the lumen. The force created by the physical interaction of the lumen and the electronic assembly 200, may be at least partially dependent on a curvature (curvature=1/R, where R is the radius of its osculating circle at a point long a curve) along the edges of the pads 208/236.
It may be desirable to mitigate the forces and/or abrupt changes in forces between the composite structure and the lumen when the composite structure is withdrawn through the lumen, for example. In some instances, the shape of the pads 208/236 on the electronic assembly 200 may be configured to reduce the forces at the points of contact between the lumen and the composite structure. For example, in a simplistic design, as seen in
Through experimentation, it has been determined that the continuously changing curvature transition 5110 between the lead-in edge 5102 and the protruding edge 5104 of the pads 208/236 on the electronic assembly 200 may create a smoother force profile as the electronic assembly 200 contacts the lumen than the radiused curvature transition 5108. As seen in
In mathematical terms, the radiused curvature of the radiused curvature transition 5108 has a second derivative that is a constant value along the transition curve, but mathematically discontinuous at point A (e.g., where the curvature changes directions) of the radiused curvature transition 5108, which results in an abrupt or sharp change in forces at the contact between the composite structure and the lumen. On the other hand, in mathematical terms, the continuously changing curvature of the continuous curvature transition 5110 has a second derivative that is a mathematical continuous function at point A′ (e.g., where the curvature changes directions) of the continuously changing curvature transition 5110, which allows for smooth contact between the composite structure and the lumen.
Although the continuously changing curvature transition 5110 seen in
In some embodiments, the continuous curvature transition 5110 may be a continuous function. In other words, a continuous function “f” may be continuous at some point “C” of its domain if the limit of f(x) as x approaches C through the domain of f exists and is equal to f(c). This may be written as:
In detail, this may mean that three conditions: (1) f has to be defined at c, (2) the limit on the left hand side of that equation has to exist, and (3) the value of this limit must equal f(c). The function f may be said to be continuous if it is continuous at every point of its domain. This is just one example.
In some embodiments, the curvature may be considered as a simple case of a plane curve defined by the equation: y=f(x). Using primes for derivatives with respect to coordinate x, the curvature may be:
This is just one example.
In some embodiments, the curve may be parabolic and represented by the function: y=x2. The curve can be parameterized as: y(t)=(t, t2)=(x, y). Using primes for derivatives with respect to parameter t, then:
x′=1, x″=0, y′=2t, y″=2.
Substituting and dropping unnecessary absolute values results in:
This is just one example.
As a result of smooth curvature transition at point A′ (along with at other points between the lead-in edge 5102 and the protruding edge 5104 of the pads 208/236), the continuous curvature transition 5110 may have the net effect on the force that is needed to withdraw the composite structure through the lumen gently increasing and then gently decreasing as the composite structure is withdrawn through the lumen. Such smooth transition of required forces may reduce overall balloon recapture forces, reduce the potential for any snagging that sharper contours (e.g., radiused curvatures) may present, promote refolding of the balloon, and/or provide other benefits.
In experimentation, the utilization of a continuously changing curvature transition 5110 for pads 208/236 of an electrode assembly on a balloon catheter has been shown to be beneficial when the electrode assembly 200 (e.g., a stiff structure) is folded such that it completely pancakes onto the balloon (e.g., a less stiff structure). The benefits, however, of a continuously changing curvature transition 5110 have been shown to inure when the composite structure is folded to one or more shapes (e.g., S-shape, U-shape, etc.) other than the shape of a pancake.
In some of these and in other embodiments, the distal electrode pad 208 may include a lead-in edge 5102b, a protruding edge 5104b and a transition 5110b between the lead-in edge 5102b and the protruding edge 5104b. In this example, the transition 5110b is on the opposite side of the distal electrode pad 208. The transition 5110b may be a continuously changing curvature transition. Thus, the transition 5110b may help to reduce recapture forces, reduce snagging, increase the ability of the balloon to more easily fold and/or refold after use, and/or reduce delamination.
In some embodiments, the transition 5110a may be the same function as the transition 5110b. In other words, the continuously changing curve along the transition 5110a may be same as along the transition 5110b. In other embodiments, the transitions 5110a/5110b may differ. For example, the continuously changing curve along the transition 5110a may be different than the transition 5110b.
Similar transitions may be utilized for the distal electrode pad 208.
Some of the dimensions and/or shapes contemplated for the electrode assembly 200 are shown in
Proximal tail 238 may extend proximally from the proximal electrode pad 236. In at least some embodiments, the proximal electrode pad 236 may be centered with the proximal tail 238. In other words, the proximal tail 238 may be positioned so that it joins with the middle of the proximal electrode pad 236. Accordingly, the proximal electrode pad 236 may extend laterally relative to or otherwise from the proximal tail 238 in an essentially symmetrical manner (e.g., extending laterally the same distance from the proximal tail 238 on both sides). It can also be seen that the angle formed by the proximal electrode pad 236 and the proximal tail 238 where the proximal electrode pad 236 extends laterally is substantially the same on both sides of the proximal electrode pad 236. This arrangement may be desirable for a number of reasons. For example, by centering the proximal electrode pad 236 with the proximal tail 238, it may be less likely for the proximal electrode pad 236 to snag or catch on the end of a catheter or sleeve if the electrode assembly 200 is retracted therein.
It should also be understood that in other embodiments, the intermediate tail 228, which may also be centered on the distal electrode pad 208. For example, intermediate tail 228 may extend between the pads 208/236, and may be centered on the proximal electrode pad 236, the distal electrode pad 208, or both pads 208/236. In other words, the intermediate tail 228 may be positioned so that it joins with the middle of the proximal electrode pad 236, the middle of the distal electrode pad 208, or the middle of both pads 208/236. Accordingly, the proximal electrode pad 236, the distal electrode pad 208, or both, may extend laterally relative to or otherwise from the intermediate tail 228 in an essentially symmetrical manner (e.g., extending laterally the same distance from the intermediate tail 228 on both sides). In some cases, the angle formed by the proximal electrode pad 236 and the intermediate tail 228 where the proximal electrode pad 236 extends laterally is substantially the same on both sides of the proximal electrode pad 236. Similarly, in some cases, the angle formed by the distal electrode pad 208 and the intermediate tail 228 where the distal electrode pad 208 extends laterally is substantially the same on both sides of the distal electrode pad 208. This arrangement may be desirable for a number of reasons. For example, by centering the proximal electrode pad 236 and/or distal electrode pad 208 with the intermediate tail 228, it may be less likely for the electrode pad 236 to snag or catch on the end of a catheter or sleeve if the electrode assembly 200 is advanced and/or retracted therein.
The ground trace 210 and active electrode trace 212 of
As shown in
It has been experimentally determined that an example embodiment for a renal hypertension indication having an approximate longitudinal length of 4 mm per plurality of electrodes, including longitudinal spacing between electrodes 222, provides effective tissue remodeling results with respect to optimal lesion size and depth, while avoiding a stenoic response. The shown configuration was arrived at by balancing depth of thermal penetration, and avoidance of thermal damage to tissue collateral the treatment zone, while seeking to minimize the number of electrode pairs to optimize flexibility and profile on a final device. However, the shown configuration is not a necessary requirement, since electrode size and placement geometry can vary according to desired therapeutic effect.
Thirty-three Yorkshire swine were subjected to renal denervation (RDN) by Vessix Vascular's renal denervation radiofrequency (RF) balloon catheters. Putative renal denervation through Vessix Vascular's electrode design was accomplished through a spectrum of settings (a function of electrode length, temperature, and duration) to compare the safety at 7 days and 28 days post-procedure between Vessix 16 mm circumferential electrodes vs. 2 mm and 4 mm electrode with offset design. Histologic sections of the renal arteries were examined to evaluate the tissue response including, but not limited to: injury, inflammation, fibrosis, and mineralization at 7 and 28 days.
The treatment of renal arteries with the Vessix Vascular RDN RF Balloon Catheter resulted in a spectrum of changes in the arterial wall and adjacent adventitia, which represented the progression of the arterial/adventitial response from an acute, “injurious” phase to a chronic, “reactive/reparative” phase. Treated areas within the renal arteries were apparent due to the presence of these changes in the arterial wall and extension thereof into the adjacent adventitial tissue (interpreted as the “zone of treatment”).
At Day 7, all electrodes, regardless of length, treatment temperature or duration were associated with a primarily injurious response. However, the 2 mm and 4 mm electrodes were also associated with an early reactive/reparative response, regardless of treatment duration, which was not observed with either 16 mm RF treatment at Day 7. The overall extent of arterial circumference affected with the 16 mm electrodes was increased (mild/moderate to marked, ˜>75% to 100% of circumference covered, respectively), regardless of temperature, relative to the shorter electrodes (2 mm and 4 mm) in which the affect was typically minimal to mild/moderate (˜<25% to ˜25-75% circumference affected, respectively), regardless of duration of treatment.
At Day 28, frequent, minimal neointima formation was observed, regardless of time point, in all treatment groups with the exception of the shorter 4 mm electrode. Mild/moderate neointima formation was infrequently observed only at Day 28, regardless of treatment group; however, the 16 mm electrodes were associated with a mild and comparable increase in the incidences of mild/moderate neointima relative to the shorter 2 and 4 mm electrode.
The denudation (i.e., loss) of endothelial cells is a common sequelae to the passage of any interventional device as well as an expected sequelae to the treatment with the Vessix Vascular RDN RF Balloon Catheter. Due to the importance of the endothelium in preventing thrombus formation, its recovery in denuded regions was monitored. As such, the magnitude/extent of the re-endothelialization of the luminal surface was interpreted relative to the approximate circumference of the artery affected
At Day 7, the 2 and 4 mm electrodes had more arterial sections with complete endothelialization than not; complete endothelialization was present in all arterial sections of the 2 and 4 mm electrode. No arterial section treated with a 16 mm electrode was observed to have complete endothelialization at Day 7, regardless of dose.
At Day 7, inflammation was overall typically minimal, regardless of treatment; however, both 16 mm electrodes, regardless of dose, had an overall increase in inflammation relative to 2 and 4 mm electrodes. Mild/moderate inflammatory infiltrates were rarely observed in the 2 and 4 mm electrode, but were frequent to common in the 16 mm electrodes.
In the embodiment of
While it is an important design optimization consideration to balance the thickness of the gold above the insulating layer 206 so as to achieve good flexibility while maintaining sufficient height so as to provide good tissue contact, this is counterbalanced with the goal of avoiding a surface height that may snag during deployment or collapse of the balloon. These issues vary according to other elements of a particular procedure, such as balloon pressure. For many embodiments, it has been determined that electrodes that protrude approximately 0.025 mm above the insulating layer 206 will have good tissue contact at balloon inflation pressures below 10 atm and as low as 2 atm. These pressures are well below the typical inflation pressure of an angioplasty balloon.
The sensor trace 214 is centrally located on the distal electrode pad 208 and includes a sensor power pad 224 facing the sensor ground pad 218. These pads can connect to power and ground poles of a heat sensing device 226, such as a thermocouple (for example, Type T configuration: Copper/Constantan) or thermistor, as shown in the partial cross-section depicted in
The heat sensing device 226 is proximately connected to the sensor power pad 224 and distally connected to the sensor ground pad 218. To help reduce overall thickness, the heat sensing device 226 is positioned within an opening within the base layer 202. In some embodiments, the heat sensing device 226 is a thermistor having a thickness of 0.1 mm, which is unusually thin—approximately two-thirds of industry standard. As shown, the heat sensing device 226 is on a non-tissue contacting side of the distal electrode pad 208. Accordingly, the heat sensing device 226 is captured between the electrode structure and a balloon when incorporated into a final device, such as catheter 120. This is advantageous since surface-mounted electrical components, like thermistors, typically have sharp edges and corners, which can get caught on tissue and possibly cause problems in balloon deployment and/or retraction. This arrangement also keeps soldered connections from making contact with blood, since solder is typically non-biocompatible. Further, due to the placement of the heat sensing device, it can measure temperature representative of tissue and the electrodes 222. Designs in the prior art typically take one of two approaches—either contacting tissue or contacting the electrode. Here, neither of these prior approaches are employed.
From the rectangular distal electrode pad 208, the combined base layer 202, conductive layer 204, and insulating layer 206 reduce in lateral width to an intermediate tail 228. Here, the conductive layer 204 is formed to include an intermediate ground line 230, intermediate active electrode line 232, and intermediate sensor line 234, which are respectively coextensive traces of the ground trace 210, active electrode trace 212, and sensor trace 214 of the distal electrode pad 208.
From the intermediate tail 228, the combined base layer 202, conductive layer 204, and insulating layer 206 increase in lateral width to form a proximal electrode pad 236. The proximal electrode pad 236 is constructed similarly to the distal electrode pad 208, with the electrode geometry and heat sensing device arrangement being essentially identical, although various differences may be present. However, as shown, the proximal electrode pad 236 is laterally offset from the distal electrode pad 208 with respect to a central axis G-G extending along the intermediate ground line 230. The intermediate active electrode line 232 and intermediate sensor line 234 are laterally coextensive with the proximal electrode pad 236 on parallel respective axes with respect to central axis G-G.
From the proximal electrode pad 236, the combined base layer 202, conductive layer 204, and insulating layer 206 reduce in lateral width to form a proximal tail 238. The proximal tail 238 includes a proximal ground line 240, proximal active electrode line 242, and proximal sensor line 244, as well the intermediate active electrode line 232 and intermediate sensor line 234. The proximal tail 238 includes connectors (not shown) to enable coupling to one or more sub-wiring harnesses and/or connectors and ultimately to control unit 110. Each of these lines are extended along parallel respective axes with respect to central axis G-G.
As shown, the electrode assembly 200 has an asymmetric arrangement of the distal electrode pad 208 and proximal electrode pad 236, about axis G-G. Further, the ground electrodes of both electrode pads are substantially aligned along axis G-G, along with the intermediate and proximal ground lines 230/240. It has been found that this arrangement presents many advantages. For example, by essentially sharing the same ground trace, the width of the proximal tail is only about one and a half times that of the intermediate tail 228, rather than being approximately twice as wide if each electrode pad had independent ground lines. Thus, the proximal tail 238 is narrower than two of the intermediate tails 228.
Further, arranging the electrode pads to share a ground trace allows control of which electrodes will interact with each other. This is not immediately apparent when viewing a single electrode assembly, but becomes evident when more than one electrode assembly 200 is assembled onto a balloon, for example as shown in
In some embodiments, the common ground typically carries 200 VAC at 500 kHz coming from the negative electrode pole, and a 1V signal from the heat sensing device 226 (in the case of a thermistor) that requires filtering of the RF circuit such that the thermistor signal can be sensed and used for generator control. In some embodiments, because of the common ground, the thermistor of the adjacent electrode pair may be used to monitor temperature even without firing the adjacent electrode pair. This provides the possibility of sensing temperatures proximate to both the distal electrode pad 208 and the proximal electrode pad 236, while firing only one of them.
Referring again to
Balloon surface area maximization is also enabled in part by laterally offsetting both electrode pads of each electrode assembly 140a-d. For example, the rightwards lateral offset of each distal electrode pad 150a-d and the leftwards lateral offset of the proximal electrode pad 170a-d allow adjacent electrode pad assemblies to key into one another such that some of the electrode pads laterally overlap one another. For example, the distal electrode pad 150a of electrode assembly 140a laterally overlaps with proximal electrode pad 170b of electrode assembly 140b. Further, the distal electrode pad 150b of electrode assembly 140b laterally overlaps with the proximal electrode pad 170c of electrode assembly 140c. However, the length of each intermediate tail prevents circumferential overlap (longitudinal overlap in this view) of the electrode pads, thus maintaining the non-contiguous nature of the treatment zones in the longitudinal direction L-L.
The arrangement and geometry of the electrode pads, as well as the arrangement and geometry of the tails of the flexible circuits may also facilitate folding or otherwise collapsing the balloon into a relatively compact un-expanded state. For instance, in embodiments with an expanded diameter of up to 10 mm, the device in an un-expanded state may have as low as an approximately 1 mm diameter.
Some embodiments utilize a standard electrode assembly having identical dimensions and construction, wherein the number and relative position of electrode assemblies on an outer surface of a balloon becomes a function of balloon diameter and/or length while electrode assembly geometries remain unchanged amongst various balloon sizes. The relative positioning of electrode assemblies relative to balloon diameter and/or length may then be determined by the desired degree or avoidance of circumferential and/or axial overlap of adjacent electrode pads of neighboring electrode assemblies on a balloon of a given size. In other embodiments, however, all of the electrode assemblies on the balloon will not necessarily be identical.
The electrode assemblies of
Treatment Methods and Control Systems
a. Device Positioning
In some embodiments, control unit 110 may measure impedance at the electrode assemblies to confirm apposition of the electrodes with the body passageway. In at least some of these embodiments, the treatment may proceed even if apposition is not sensed for all of the electrodes. For instance, in some embodiments, the treatment may proceed if apposition is sensed for 50% or more of the electrodes, and may allow for less than complete uniformity of apposition circumferentially and/or axially. For example, in some instances the catheter may be positioned such that one or more of the proximal electrodes are in the aorta and exposed to blood, and impedance sensed for such electrodes may not fall within a pre-designated range (such as, for example, 500-1600 ohms), indicating an absence of tissue apposition for those electrodes. In some instances, the system may allow for user authorization to proceed with the treatment even if there is less than uniform electrode/tissue apposition. Subsequently, the control unit 110 may activate the electrodes to create a corresponding number of lesions L, as indicated by the black squares. During activation of the electrodes, the control unit uses heat sensing devices of the electrode pads to monitor both heat of the electrode and the tissue due to the unique arrangement of the heat sensing devices, which do not contact either tissue or electrodes. In this manner, more or less power can be supplied to each electrode pad as needed during treatment.
In some embodiments, control unit 110 may apply a uniform standard for determining apposition to all the electrodes of the device. For instance, the control unit may utilize the same pre-designated range of resistance measurements to all of the electrodes. In other instances, however, including some, although not all, monopolar applications, different standards may be applied to different monopolar electrodes for determining apposition. For example, in some monopolar embodiments, each monopolar electrode may define a discrete electrical circuit through the tissue to the common/indifferent electrode (or electrodes), and the characteristics of those circuits (e.g. resistance) may vary significantly based on the distance between the monopolar electrode and common electrode, the tissue characteristics therebetween, and other geometries and characteristics of the device and surrounding tissue. As such, in at least some embodiments, it may be desirable to apply criteria for determining apposition that varies depending on, e.g., the distance between the monopolar electrode and common electrode (e.g. the greater the distance between the two electrodes, the higher the impedance measurement required to determine good apposition). In other embodiments, however, the variance due to these differences in distance and other geometries will be minimal or non-substantive, and a uniform standard may be applied.
Returning to
In some instances, alternative methods other than those illustrated in
Referring again to the example of renal hypertension involving the reduction of excessive nerve activity, the system may be used to effect a non-piercing, non-ablating way to direct energy to affect nerve activity. Accordingly the body passage shown can be a renal artery surrounded by nerve tissue N in sections S1-S3. Electrodes on the expandable device may be powered to deliver energy in the known direction of a nerve N to be affected, the depth of energy penetration being a function of energy dosage, electrode type (e.g. monopolar vs. bipolar) and electrode geometry. U.S. Pub. No. 2008/0188912 entitled “System for Inducing Desirable Temperature Effects on Body Tissue”, the full disclosure of which is incorporated herein by reference, describes some considerations for electrode geometry and the volume of tissue treatment zones that may be taken into account in some, although not necessarily all, embodiments. In some instances, empirical analysis may be used to determine the impedance characteristics of nervous tissue N such that catheter device may be used to first characterize and then treat tissue in a targeted manner as disclosed and described herein. The delivery and regulation of energy may further involve accumulated damage modeling as well.
As shown, each lesion L is created in a corresponding treatment zone A-D of the expandable device 130. Accordingly, any lesion L made in one particular treatment A-D zone will not circumferentially overlap with a lesion of an adjacent treatment zone A-D at any point along the operational axis O-O. In some embodiments, a treatment zone of the expandable device 130 can have more than one electrode pad, and thus in such cases, lesions L created by those electrode pads can circumferentially overlap. In those cases, more lesions L may be required for a particular anatomy or a pair of electrode pads are required for performing a diagnostic routine before therapy is applied. Regardless, circumferential overlap of electrodes of adjacent treatment zones will not be present.
b. Energy Delivery
Depending on the particular remodeling effect required, the control unit may energize the electrodes with about 0.25 to 5 Watts average power for 1 to 180 seconds, or with about 0.25 to 900 Joules. Higher energy treatments may be done at lower powers and longer durations, such as 0.5 Watts for 90 seconds or 0.25 Watts for 180 seconds. In monopolar embodiments, the control unit may energize the electrodes with up to 30 Watts for up to 5 minutes, depending on electrode configuration and distance between the electrodes and the common ground. A shorter distance may provide for lower energy for a shorter period of time because energy travels over more localized area with fewer conductive losses. In an example embodiment for use in renal denervation, energy is delivered for about 30 seconds at a treatment setting of about 5 Watts, such that treatment zones are heated to about 68° C. during treatment. As stated above, power requirements may depend heavily on electrode type and configuration. Generally, with wider electrode spacing, more power is required, in which case the average power could be higher than 5 Watts, and the total energy could exceed 45 Joules. Likewise, using a shorter or smaller electrode pair would require scaling the average power down, and the total energy could be less than 4 Joules. The power and duration may be, in some instances, calibrated to be less than enough to cause severe damage, and particularly less than enough to ablate diseased tissue within a blood vessel. The mechanisms of ablating atherosclerotic material within a blood vessel have been well described, including by Slager et al. in an article entitled, “Vaporization of Atherosclerotic Plaque by Spark Erosion” in J. of Amer. Cardiol. (June, 1985), on pp. 1382-6; and by Stephen M. Fry in “Thermal and Disruptive Angioplasty: a Physician's Guide”; Strategic Business Development, Inc., (1990), the full disclosure of which is incorporated herein by reference.
In some embodiments, energy treatments applied to one or both of the patient's renal arteries may be applied at higher levels than would be possible in other passageways of the body without deleterious effects. For instance, peripheral and coronary arteries of the body may be susceptible to a deleterious long-term occlusive response if subjected to heating above a certain thermal response limit. It has been discovered that renal arteries, however, can be subjected to heating above such a thermal response limit without deleterious effect.
In some embodiments, energy treatments may be applied to one or both of the patient's renal arteries to affect sympathetic nerve activity in the kidneys in order to moderate both systolic and diastolic forms of CHF. The application of therapeutic thermal energy to the tissues proximate the renal artery may be effective in reducing the sympathetic nerve activity so as to mitigate the biological processes and the resulting effects of CHF. In some embodiments, a mild application of a controlled dose of thermal energy in a rapid procedure (e.g. 10 minutes or less of therapy time per kidney) is used so as to provide a simple procedure for the clinical staff while providing a procedure that minimizes the pain felt by a patient while maximizing the efficacy of the procedure. The balloon-mounted electrodes and energy delivery methods of the present disclosure may be particularly well suited for the application of energy to reduce sympathetic nerve activity related to chronic hypertension, in conjunction with or separate from, systolic and diastolic CHF.
In some embodiments, the electrode pads described herein may be energized to assess and then selectively treat targeted tissue to achieve a desired therapeutic result by a remodeling of the treated tissue. For example, tissue signature may be used to identify tissue treatment regions with the use of impedance measurements. Impedance measurements utilizing circumferentially spaced electrodes within a body passage may be used to analyze tissue. Impedance measurements between pairs of adjacent electrodes may differ when the current path passes through diseased tissue, and when it passes through healthy tissues of a luminal wall for example. Hence, impedance measurements between the electrodes on either side of diseased tissue may indicate a lesion or other type of targeted tissue, while measurements between other pairs of adjacent electrodes may indicate healthy tissue. Other characterization, such as intravascular ultrasound, optical coherence tomography, or the like, may be used to identify regions to be treated either in conjunction with, or as an alternate to, impedance measurements. In some instances, it may be desirable to obtain baseline measurements of the tissues to be treated to help differentiate adjacent tissues, as the tissue signatures and/or signature profiles may differ from person to person. Additionally, the tissue signatures and/or signature profile curves may be normalized to facilitate identification of the relevant slopes, offsets, and the like between different tissues. Impedance measurements can be achieved at one or more frequencies, ideally two different frequencies (low and high). Low frequency measurement can be done in range of about 1-10 kHz, or about 4-5 kHz and high frequency measurement can be done in range of about 300 kHz-1 MHz, or between about 750 kHz-1 MHz. Lower frequency measurement mainly represents the resistive component of impedance and correlates closely with tissue temperature where higher frequency measurement represents the capacitive component of impedance and correlates with destruction and changes in cell composition.
Phase angle shift between the resistive and capacitive components of impedance also occurs due to peak changes between current and voltage as result of capacitive and resistive changes of impedance. The phase angle shift can also be monitored as means of assessing tissue contact and lesion formation during RF denervation.
In some embodiments, remodeling of a body lumen can be performed by gentle heating in combination with gentle or standard dilation. For example, an angioplasty balloon catheter structure having electrodes disposed thereon might apply electrical potentials to the vessel wall before, during, and/or after dilation, optionally in combination with dilation pressures which are at or significantly lower than standard, unheated angioplasty dilation pressures. Where balloon inflation pressures of 10-16 atmospheres may, for example, be appropriate for standard angioplasty dilation of a particular lesion, modified dilation treatments combined with appropriate electrical potentials (through flexible circuit electrodes on the balloon, electrodes deposited directly on the balloon structure, or the like) described herein may employ from 10-16 atmospheres or may be effected with pressures of 6 atmospheres or less, and possibly as low as 1 to 2 atmospheres. Such moderate dilation pressures may (or may not) be combined with one or more aspects of the tissue characterization, tuned energy, eccentric treatments, and other treatment aspects described herein for treatment of body lumens, the circulatory system, and diseases of the peripheral vasculature.
In many embodiments, gentle heating energy added before, during, and/or after dilation of a body lumen may increase dilation effectiveness while lowering complications. In some embodiments, such controlled heating with a balloon may exhibit a reduction in recoil, providing at least some of the benefits of a stent-like expansion without the disadvantages of an implant. Benefits of the heating may be enhanced (and/or complications inhibited) by limiting heating of the adventitial layer below a deleterious response threshold. In many cases, such heating of the intima and/or media may be provided using heating times of less than about 10 seconds, often being less than 3 (or even 2) seconds. In other cases, very low power may be used for longer durations. Efficient coupling of the energy to the target tissue by matching the driving potential of the circuit to the target tissue phase angle may enhance desirable heating efficiency, effectively maximizing the area under the electrical power curve. The matching of the phase angle need not be absolute, and while complete phase matching to a characterized target tissue may have benefits, alternative systems may pre-set appropriate potentials to substantially match typical target tissues; though the actual phase angles may not be matched precisely, heating localization within the target tissues may be significantly better than using a standard power form.
In some embodiments, monopolar (unipolar) RF energy application can be delivered between any of the electrodes on the balloon and return electrode positioned on the outside skin or on the device itself, as discussed above. Monopoloar RF may be desirable in areas where deep lesions are required. For example, in a monopolar application, each electrode pair may be powered with positive polarity rather than having one positive pole and one negative pole per pair. In some embodiments, a combination of monopolar and bipolar RF energy application can be done where lesions of various depth/size can be selectively achieved by varying the polarity of the electrodes of the pair.
c. Target Temperature
The application of RF energy can be controlled so as to limit a temperature of target and/or collateral tissues, for example, limiting the heating of target tissue such that neither the target tissue nor the collateral tissue sustains irreversible thermal damage. In some embodiments, the surface temperature range is from about 50° C. to about 90° C. For gentle heating, the surface temperature may range from about 50° C. to about 70° C., while for more aggressive heating, the surface temperature may range from about 70° C. to about 90° C. Limiting heating so as to inhibit heating of collateral tissues to less than a surface temperature in a range from about 50° C. to about 70° C., such that the bulk tissue temperature remains mostly below 50° C. to 55° C., may inhibit an immune response that might otherwise lead to stenosis, thermal damage, or the like. Relatively mild surface temperatures between 50° C. and 70° C. may be sufficient to denature and break protein bonds during treatment, immediately after treatment, and/or more than one hour, more than one day, more than one week, or even more than one month after the treatment through a healing response of the tissue to the treatment so as to provide a bigger vessel lumen and improved blood flow.
In some embodiments, the target temperature may vary during the treatment, and may be, for instance, a function of treatment time.
Both bench top and animal experimentation were undertaken to optimize and verify the target temperature profile used in denervation embodiments of the Vessix system. The following summarizes the bench top experimentation and analysis supporting the selection of the medium enhanced rise temperature profile as an example embodiment.
The tests were carried out to determine which rise time algorithm would provide optimal levels of effectiveness and safety. Some previous rise time algorithms had simply gone up to the set temperature as fast as possible, and it was believed that this was not necessarily the best course of action in at least some circumstances. Efficacy was qualitatively assessed with three dimensionless parameters. The objective was to determine the algorithm that would produce the least amount of charring, denaturing, and dehydrating of the tissue at the treatment zone, based on visual inspection, while also providing good efficacy.
A water bath was brought up to 37° C. to simulate body temperature, and a liver sample was placed in the bath to simulate conditions in vivo. Good apposition of the device was verified by noting the impedance values of the electrode-tissue interface of each bipolar electrode pair in contact with tissue. A higher impedance (>500 Ohms) was used as the benchmark for good apposition.
After the temperature profiles of
After carefully reviewing all of the experimental data, it was decided that the medium enhanced rise profile was the best temperature rise algorithm to use for certain embodiments, although, again, other target temperature profiles may also be appropriately used in conjunction with the disclosed embodiments of the present disclosure.
d. Control Algorithm
In some embodiments, it will be desirable to regulate the application of RF or other energy based on target temperature profiles such as those described above to provide for a gentle, controlled, heating that avoids application of high instantaneous power and, at a microscopic level, associated tissue searing or other damage, which could undesirably result in heat block or otherwise cause a net reduction in thermal conduction heat transfer at the device/tissue interface. In other words, by avoiding higher swings in temperature and the resultant heavier instantaneous application of energy to reestablish temperature near the target temperature, tissue integrity at the immediate interface location may be preserved. Tissue desiccation may result in a net loss of thermal conductivity, resulting in reduced effective transfer of gentle, therapeutic delivery of energy to target tissues beyond the electrode/tissue interface.
Those of skill in the art will appreciate that although the particular control method of
In general, the control method embodiment of
The output setting of the generator and switching of the electrodes may be determined by a feedback loop that takes into account measured temperature as well as previous desired output settings. During a particular treatment cycle (e.g. a 25 millisecond slice of the treatment), each of the electrodes may be identified for one of three states: off, energized, or measuring. In some embodiments, electrodes will only be in energized and/or measuring states (an electrode that is energized may also be measuring) if they meet certain criteria, with the default electrode state being off. Electrodes that have been identified as energized or measuring electrodes may have voltage applied or be detecting temperature signals for a portion of the cycle, or for the entire cycle.
The control loop embodiment of
The control loop embodiment of
As indicated at step 1300, each electrode is initially set to off. At step 1302, one of the electrodes is designated as a primary electrode for that treatment cycle. As discussed in further detail below, during the treatment, the primary electrode designated will vary from treatment cycle to treatment cycle (e.g. cycle through all of the available electrodes). The determination of which electrode will be designated as the primary electrode may be done by accessing a look-up table or using any other suitable functionality for identifying a primary electrode and varying the choice of primary electrode from treatment cycle to treatment cycle.
At step 1302, additional electrodes may also be designated as candidate electrodes for energization and/or measuring during that treatment cycle. The additional electrodes designated may be candidates by virtue of being in a certain relationship or lacking a certain relationship relative to the designated primary electrode for that treatment cycle.
For instance, in some bipolar electrode embodiments, some of the electrodes on the electro-surgical device may be arranged in a manner such that there may be a potential for current leakage between the primary electrode and those other electrodes if both the primary electrode and those additional electrodes are energized simultaneously in a treatment cycle, which may undesirably cause interference with the temperature measurement by the associated heat sensing device, imprecision in the amount of energy delivered at each electrode, or other undesirable consequences. For instance, in the embodiment illustrated in
As another non-limiting example, in some monopolar electrode embodiments, the candidate electrodes are the monopolar electrodes that have similar measured or estimated electrical circuit properties to one or more measured or estimated properties of the electrical circuit associated with the primary electrode. In other words, in some monopolar systems, it may be desirable to only simultaneously energize monopolar electrodes that define substantially similar electrical circuits to the electrical circuit defined by the primary monopolar electrode (e.g. the circuit defined by the monopolar electrode, the common electrode, and a pathway through the patient's tissue). In some instances, this may facilitate uniformity in current flow during energization. In other embodiments, a pre-defined table or other listing or association will determine which electrodes are candidate electrodes based on the current primary electrode.
In at least some embodiments, switches associated with non-candidates will be opened to isolate the non-candidates from the rest of the system's circuitry. This switching, in at least some embodiments, could also or alternatively be used to otherwise maximize the number of available electrode pairs available for energization provided that a common ground between pairs is not affected by the switching off.
In other embodiments, the electro-surgical device may be configured to avoid the potential for leakage or otherwise take such leakage into account, and, accordingly, all the electrodes of the device may be candidates for energization and/or measuring during a treatment cycle.
In some embodiments, the assignment of an electrode as either the primary electrode, candidate, or non-candidate may be determined by a sequence matrix or look up table in an array that identifies the status of each of the electrodes and an order for the designation of primary electrodes. In one non-limiting embodiment, the primary electrode designation cycles circumferentially through the proximate electrodes and then circumferentially through the distal electrodes (e.g. in
In some embodiments, additional conditions may result in a particular electrode being set to off for a particular treatment cycle and/or for the remainder of the treatment. For instance, as discussed below, during the course of treatment, as much as 4° C. temperature overshoot may be allowed (e.g., even if such overshoot results in the electrode not being energized, it will not necessarily be set to off and still available for measuring); however, in at least some embodiments, if eight consecutive treatment cycles measure temperature overshoot for a particular electrode, that electrode will be set to off for the remainder of the treatment, with the treatment otherwise continuing and without otherwise changing the control loop process discussed below.
At step 1304, target voltages for each of the primary and other candidate electrodes are determined. In this particular embodiment, a target voltage for a particular electrode may be determined based on a temperature error associated with the treatment site of that electrode as well as the last target voltage calculated (although not necessarily applied) for that electrode. Temperature error may be calculated by measuring the current temperature at the treatment site (e.g. utilizing the heat sensing device associated with the electrode proximate that treatment site) and determining the difference between the measured temperature and the target temperature for that instant of time in the treatment.
Those of skill in the art will appreciate that while this particular embodiment is described as using voltage as a control variable, that power could be used as an alternative to voltage for the control variable, based on, for instance, a known relationship between power and voltage (i.e. power equaling voltage times current or impedance).
V=KLVL+KPTe+KI∫tt-n secTe AVE
In some embodiments, including the embodiment of
In some embodiments, it may be beneficial to use only the last assigned electrode voltage for determining a target voltage, rather than utilizing averages of voltages or voltages from earlier treatment cycles, as, in some cases, use of earlier voltages may be a source for computational error in embodiments that focus on fine control of the target temperature.
Returning to
At step 1312, the primary and other candidate electrodes with a target voltage greater than zero are identified as electrodes to be energized. In alternative embodiments, candidate electrodes other than the primary will only be energized if the target voltages determined for those electrodes is 6V greater than the set voltage.
In still other embodiments, candidate electrodes other than the primary will only be energized if the target voltages determined for these electrodes are 1, 5 or 10V greater than the set voltage.
At step 1314, it is determined whether the electrodes to be energized are currently at temperatures greater than 68° C. Those electrodes that are at temperatures greater than 68° C. are switched off or otherwise prevented from being energized in that treatment cycle, and those electrodes otherwise meeting the above criteria are energized at the set voltage at step 1316. Subsequently, another treatment cycle begins, and the control loop of
It has been experimentally determined that an example embodiment of the temperature control method described above, when employed as part of the Vessix System for Renal Denervation, provides effective reduction of norepinephrine (NEPI) concentration. In one experiment, efficacy and safety of the Vessix System for Renal Denervation was assessed in healthy juvenile Yorkshire swine at 7 and 28 days post-treatment, including an assessment of kidney NEPI concentration levels at 7 days post-treatment.
e. Nerve Signal Stimulation and Monitoring
In at least some of the embodiments described above, or in alternative embodiments, renal-denervation treatment methods and systems may provide for stimulation of nerve signals and monitoring for nerve signal response in the tissue proximate the treated renal artery. In some instances, this electrogram of neural activity may provide an assessment of the denervation treatment's efficacy and/or provide feedback for regulating the treatment. In at least some embodiments, such an electrogram provides for an assessment of whether neural activity is present and/or has shifted (e.g. decreased) relative to a measured baseline, and does not involve mapping or quantifying the presence of neural tissue proximate the renal artery.
In one embodiment, the same electrode assemblies used to deliver the denervation treatment, such as the bi-polar electrode pairs on the distal and proximal electrode pads 150a-d and 170a-d shown in
Electrodes 222 having the size, spacing, other geometries and other characteristics as described above in the context of
In alternative embodiments, the electrodes used to stimulate and/or monitor for nerve signals may be different from the electrodes used to deliver the energy treatment. The stimulation/monitoring electrodes may have positions, geometries, and other characteristics optimized for stimulation/monitoring and the energy delivery electrodes may have positions, geometries and other characteristics optimized for delivering the energy treatment.
In monopolar embodiments, the electrodes serve as the positive pole for stimulating and sensing during treatment, while a separate negative pole is used as a ground. The negative pole may be located on the expandable structure, at one or more points on the catheter body, or external to the patient in the form of a grounding pad. In monopolar configurations, signal processing and filtering (as further described below) are desirable options because of the relatively large difference in magnitudes between energy delivery and nerve response detection.
The RF generator and other circuitry of the control unit 110 shown and described for
In one embodiment, the nerve stimulation may be a voltage in the range of about 0.1V to about 5V, or about 0.5V, applied by the first electrode for a period of about 1 second or less, or about 0.5 milliseconds, followed by a pulse width modulation, which may shock a nerve tissue into propagating a nerve signal. The pulse signal may be of any form with a square wave being one example form because the rapid on/off nature of the wave form efficiently stimulates a nerve response with no ramp to or from peak voltage.
Neural activity may be assessed by measuring one or more of amplitude of the nerve signal in response to the stimulation, speed of the nerve signal in response to the stimulation, and/or fractionated amplitude of the nerve signal. Here, a fractionated amplitude refers to a net reduction and change to the nerve conduction signal as compared to a pre-treatment baseline. A pre-treatment signal would be expected to have a relatively larger amplitude and smoother transition of slope while a signal from a nerve having received at least some treatment would be expected to have a relatively lower amplitude and a less smooth, sudden, or broken transition in slope indicative of interrupted nerve conduction due to treatment. These measurements can be determined by measuring a change in voltage at the second electrode and/or a measured time between the stimulation and the response, and, in at least some embodiments, may utilize high and/or low pass filtering to differentiate the nerve signal from background noise.
Currently, interventional energy delivery therapies such as renal denervation are performed based on anatomical landmarks. In the example of renal denervation, it is known that a majority of nerves are located along the length of renal arteries. Post treatment assessment is based on secondary effects such as NEPI and blood pressure reductions, which are not typically immediate indicators and are not indicative of nerve viability.
In the current state of the art there is no means available to directly assess functional behavior of renal nerves in real-time during a renal denervation procedure. A solution to this problem is the use of alternating current or direct current to deliver sub-threshold or low stimulation signals in the vicinity of renal nerves within renal arteries to access their activity pre and post renal denervation treatment.
High resolution rapid nerve viability measurements may be accomplished via multiple localized electrodes such as those shown in
The measurement technique employs electric stimulation from at least one electrode over the path of a nerve to evoke the generation of an action potential that spreads along the excited nerve fibers. That action potential is then recorded on another point. This technique may be used to determine the adequacy of the conduction of the nerve impulse as it courses down a nerve, thereby detecting signs of nerve injury. The distance between electrodes and the time it takes for electrical impulses to travel between electrodes are used to calculate the speed of impulse transmission (nerve conduction velocity). A decreased speed of transmission indicates nerve damage.
Velocity, amplitude, as well as shape of the response following electrical stimulation of renal nerves will be measured via multiple electrodes on the balloon catheter. Abnormal findings include conduction slowing, conduction blockage, lack of responses, and/or low amplitude responses
Referring to
Nerve signal measurement may be optimized using signal filtering such that the influence of cardiac electrical signals, stimulation signals, and system noise are filtered out of the nerve sensing circuit so as to optimize the accuracy and sensitivity of the circuit. Signal filtering may be accomplished through means such as band-pass filters. For example, a low-pass filter in the range of about 1 Hz to about 500 Hz, with an example value of 100 Hz and a high-pass filter in the range of about 1 kHz to about 10 kHz, with an example value of 5 kHz may be employed to establish the frequency band of signals to be sensed and measured by the circuit. Measurements are then used as feedback applied to the energy control algorithm used to regulate the delivery of therapeutic energy.
In a monopolar embodiment sensing is from a broader field of tissue because energy flows from the one or more positive poles of electrodes to the negative pole or poles of a common grounding path. Applying this concept to the embodiment of
In a bipolar embodiment, sensing is from a localized field of tissue because the positive and negative poles of electrode assemblies 140a-d are immediately adjacent, and hence, the tissue volume sensed is much more localized than in a monopolar configuration. The close proximity of electrode poles in a bipolar arrangement may be desirable because the proximity of poles allows for an inherently lower quantity of energy delivery to energize tissue and an inherently higher degree of measurement resolution because of the smaller tissue volume between poles. Additionally, the electrode assembly 140a-d configurations provide a proximal/distal linear spacing that allows for the sensing and measuring the linear travel of a nerve signal along a path as has been described herein.
Nerve signal stimulation and measurement may occur before, during, and/or after the energy treatment. In one embodiment, neural activity is assessed prior to treatment to establish a baseline level of neural activity and is then reassessed after the treatment to determine whether a threshold level of change in neural activity has resulted. Any one or more of percentage reduction in nerve signal amplitude, degree of fractionation of signal slope, increase in duration of nerve signal pulse, and increase in time between nerve signal pulses may be used to measure a tissue response indicating that denervation in the target tissue has occurred or is in the process of occurring. In other words, total disruption of nerve activity may be a delayed response to the denervation treatment, although some decrease in nerve activity may occur during or just after the denervation treatment sufficient to indicate the effectiveness of the treatment. In alternative embodiments, an effective denervation may be characterized as one in which no nerve signal is detected in response to a pre-determined stimulation.
Nerve signal assessment may also or alternatively be conducted during the energy treatment. For instance, the control algorithm shown in
In some embodiments, regardless of whether the nerve activity assessment is conducted pre and post treatment, periodically between each treatment cycle, or periodically after a certain number of treatment cycles, data from the neural activity assessments may be used to establish or adjust parameters for the denervation treatment. For instance, in the embodiment illustrated by
Measuring of nerve signals may be directly integrated into the energy delivery and control methods described herein. As candidate electrodes are selected and energized in accordance with the control algorithm, the additional function of nerve signal measuring may be integrated into the control algorithm such that the additional control factor of nerve response increases the precision with which energy is delivered and a therapeutic response is achieved while avoiding the delivery of excess energy in order to preserve pre-treatment issue cellular state to the maximum degree possible. As shown in
Treatment of Small/Branched Vessels and Other Passageways
The systems and devices described herein may be advantageously used in situations where other energy-based treatment systems and devices would not be suitable. For instance, embodiments of the systems and devices described herein may be used in vessels and other passageways that are too small for treatment using other catheter-based energy treatment systems. In some instances, the systems and devices described herein may be used in renal arteries or other vessels having diameters of less than 4 mm and/or lengths of less than 20 mm. Other factors, such as vessel tortuosity and proximity of the treatment site to regions that should not receive treatment, may be contra-indications for or otherwise not suitable for treatment using earlier devices but not for at least some embodiments of the presently described systems and devices.
Other features of the systems and devices described above may also facilitate their use in vessels that are relatively small. For instance, delivering an energy treatment to a small diameter vessel may require particularly fine control over the amount of energy delivered and/or the temperature increase caused by the treatment. As such, the particular electrode energy delivery geometries, control algorithms, and other features described above may make the present systems and devices particularly suitable in such situations.
In practice, it may be possible that catheter A and catheter B are one in the same if the two arteries are sufficiently close in diameter to allow for complete balloon expansion and contact with the tissue of the arterial lumens. It may be further possible that catheter A and catheter B may be repositioned along the length of the respective arteries depending on the treatable length of each artery. It may also be further possible that the primary and accessory arteries may be treated simultaneously should a physician so desire.
To applicant's knowledge, prior to the present disclosure, the treatment of accessory renal arteries has not been possible because of technological limitations caused by overheating of small arteries, space constraints when operating in luminal areas with smaller cross sections, and the difficulty of navigating tortuous pathways. Because the embodiments of the present disclosure use expandable, catheter-based structures, flexible circuit electrodes on balloons, the limitations of “one size fits all” devices are obviated. Balloon and electrode assemblies of the present disclosure are incrementally sized and arranged to facilitate the precisely controlled thermal energy dose for an incremental range of luminal diameters. In other words, the balloon and electrode assembly is incrementally sized and arranged for optimized operation in a correspondingly sized lumen. The number of electrodes is chosen to avoid overheating of tissues. The balloon-based expandable structure is able to navigate to a location at a smaller, unexpanded diameter with flexibility. The large surface contact of an expanded balloon allows for uniformity in tissue contact while avoiding the bending and/or tight space constraints of single point probes or other such similar designs.
Accessory renal arteries are present in 25-30% of human patients; however these patients have been excluded from previous renal denervation studies. Within the REDUCE-HTN Clinical Study (the full contents of Vessix Vascular clinical study protocol CR012-020 being incorporated herein by reference) a subset of four subjects underwent successful treatment of primary and, at least, one accessory renal artery using the Vessix Renal Denervation System (Vessix Vascular, Inc.; Laguna Hills, Calif.) that includes a 0.014 inch over-the-wire percutaneous balloon catheter with up to 8 radiopaque gold electrodes mounted on the balloon surface in a longitudinally and circumferentially offset pattern. In an exemplary embodiment, a catheter is connected to a proprietary automated low-power RF bipolar generator that delivers a temperature-controlled therapeutic dose of RF energy at about 68° C. for about 30 seconds. The mean baseline office-based blood pressure (OBP) of this cohort was 189/93 mmHg. In addition to an average of 10.5 denervations of each main renal artery, this cohort was treated with an average of 8 denervations per accessory renal artery.
In this study, for the four subjects, no peri-procedural complications were reported and immediate post-procedure angiography indicated no renal artery spasm or any other deleterious effects. These four subjects demonstrated improvement at two weeks post-procedure with a mean reduction in OBP of −32/−16 mmHg (190/97 to 167/91; 175/92 to 129/70; 192/94 to 179/91; 183/87 to 138/55).
U.S. Patent Application No. 61/788,429, filed Mar. 15, 2013; U.S. patent application Ser. No. 13/725,872, filed Dec. 21, 2012; U.S. patent application Ser. No. 13/750,879, filed Jan. 25, 2013; U.S. patent application Ser. No. 13/725,843, filed Dec. 21, 2012; U.S. patent application Ser. No. 13/725,885, filed Dec. 21, 2012; U.S. patent application Ser. No. 13/725,894, filed Dec. 21, 2012; and U.S. patent application Ser. No. 13/725,904, filed Dec. 21, 2012 are all herein incorporated by reference.
While the exemplary embodiments have been described in some detail, by way of example and for clarity of understanding, those of skill in the art will recognize that a variety of modifications, adaptations, and changes may be employed.
This application claims priority under 35 U.S.C. §119 to U.S. Provisional Application Ser. No. 61/798,352, filed Mar. 15, 2013, the entirety of which is incorporated herein by reference. This application also claims priority under 35 U.S.C. §119 to U.S. Provisional Application Ser. No. 61/919,582, filed Dec. 20, 2013, the entirety of which is incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
164184 | Kiddee | Jun 1875 | A |
852787 | Hoerner | May 1907 | A |
921973 | Gillett et al. | May 1909 | A |
976733 | Gilliland | Nov 1910 | A |
1167014 | O'Brien | Jan 1916 | A |
2505358 | Gusberg et al. | Apr 1950 | A |
2701559 | Cooper | Feb 1955 | A |
3108593 | Glassman | Oct 1963 | A |
3108594 | Glassman | Oct 1963 | A |
3540431 | Mobin | Nov 1970 | A |
3952747 | Kimmell | Apr 1976 | A |
3996938 | Clark, III | Dec 1976 | A |
4046150 | Schwartz et al. | Sep 1977 | A |
4076436 | Slator | Feb 1978 | A |
4290427 | Chin | Sep 1981 | A |
4402686 | Medel | Sep 1983 | A |
4483341 | Witteles et al. | Nov 1984 | A |
4531943 | Van Tassel et al. | Jul 1985 | A |
4574804 | Kurwa | Mar 1986 | A |
4587975 | Salo et al. | May 1986 | A |
4649936 | Ungar et al. | Mar 1987 | A |
4682596 | Bales et al. | Jul 1987 | A |
4709698 | Johnston et al. | Dec 1987 | A |
4765331 | Petruzzi et al. | Aug 1988 | A |
4770653 | Shturman | Sep 1988 | A |
4784132 | Fox et al. | Nov 1988 | A |
4784162 | Ricks et al. | Nov 1988 | A |
4785806 | Deckelbaum et al. | Nov 1988 | A |
4788975 | Shturman et al. | Dec 1988 | A |
4790310 | Ginsburg et al. | Dec 1988 | A |
4799479 | Spears | Jan 1989 | A |
4823791 | D'Amelio et al. | Apr 1989 | A |
4830003 | Wolff et al. | May 1989 | A |
4849484 | Heard | Jul 1989 | A |
4862886 | Clarke et al. | Sep 1989 | A |
4887605 | Angelsen et al. | Dec 1989 | A |
4890623 | Cook et al. | Jan 1990 | A |
4920979 | Bullara | May 1990 | A |
4938766 | Jarvik | Jul 1990 | A |
4955377 | Lennox et al. | Sep 1990 | A |
4976711 | Parins et al. | Dec 1990 | A |
5034010 | Kittrell et al. | Jul 1991 | A |
5052402 | Bencini et al. | Oct 1991 | A |
5053033 | Clarke et al. | Oct 1991 | A |
5071424 | Reger et al. | Dec 1991 | A |
5074871 | Groshong et al. | Dec 1991 | A |
5098429 | Sterzer et al. | Mar 1992 | A |
5098431 | Rydell | Mar 1992 | A |
5109859 | Jenkins | May 1992 | A |
5125928 | Parins et al. | Jun 1992 | A |
5129396 | Rosen et al. | Jul 1992 | A |
5139496 | Hed | Aug 1992 | A |
5143836 | Hartman et al. | Sep 1992 | A |
5156610 | Reger et al. | Oct 1992 | A |
5158564 | Schnepp-Pesch | Oct 1992 | A |
5170802 | Mehra | Dec 1992 | A |
5178620 | Eggers et al. | Jan 1993 | A |
5178625 | Groshong et al. | Jan 1993 | A |
5190540 | Lee | Mar 1993 | A |
5211651 | Reger et al. | May 1993 | A |
5234407 | Teirstein et al. | Aug 1993 | A |
5242441 | Avitall | Sep 1993 | A |
5251634 | Weinberg et al. | Oct 1993 | A |
5255679 | Imran | Oct 1993 | A |
5263493 | Avitall | Nov 1993 | A |
5267954 | Nita et al. | Dec 1993 | A |
5277201 | Stern et al. | Jan 1994 | A |
5282484 | Reger et al. | Feb 1994 | A |
5286254 | Shapland et al. | Feb 1994 | A |
5290306 | Trotta et al. | Mar 1994 | A |
5295484 | Marcus | Mar 1994 | A |
5297564 | Love et al. | Mar 1994 | A |
5300068 | Rosar et al. | Apr 1994 | A |
5301683 | Durkan | Apr 1994 | A |
5304115 | Pflueger et al. | Apr 1994 | A |
5304121 | Sahatjian | Apr 1994 | A |
5304171 | Gregory et al. | Apr 1994 | A |
5304173 | Kittrell et al. | Apr 1994 | A |
5306250 | March et al. | Apr 1994 | A |
5312328 | Nita et al. | May 1994 | A |
5314466 | Stern et al. | May 1994 | A |
5322064 | Lundquist | Jun 1994 | A |
5324255 | Passafaro et al. | Jun 1994 | A |
5326341 | Lew et al. | Jul 1994 | A |
5326342 | Pflueger et al. | Jul 1994 | A |
5330518 | Neilson et al. | Jul 1994 | A |
5333614 | Feiring | Aug 1994 | A |
5342292 | Nita et al. | Aug 1994 | A |
5344395 | Whalen et al. | Sep 1994 | A |
5364392 | Warner et al. | Nov 1994 | A |
5365172 | Hrovat et al. | Nov 1994 | A |
5368557 | Nita et al. | Nov 1994 | A |
5368558 | Nita et al. | Nov 1994 | A |
5380274 | Nita et al. | Jan 1995 | A |
5380319 | Saito et al. | Jan 1995 | A |
5382228 | Nita et al. | Jan 1995 | A |
5383874 | Jackson et al. | Jan 1995 | A |
5383917 | Desai et al. | Jan 1995 | A |
5397301 | Pflueger et al. | Mar 1995 | A |
5397339 | Desai | Mar 1995 | A |
5401272 | Perkins et al. | Mar 1995 | A |
5403311 | Abele et al. | Apr 1995 | A |
5405318 | Nita et al. | Apr 1995 | A |
5405346 | Grundy et al. | Apr 1995 | A |
5409000 | Imran | Apr 1995 | A |
5417672 | Nita et al. | May 1995 | A |
5419767 | Eggers et al. | May 1995 | A |
5427118 | Nita et al. | Jun 1995 | A |
5432876 | Appeldorn et al. | Jul 1995 | A |
5441498 | Perkins et al. | Aug 1995 | A |
5447509 | Mills et al. | Sep 1995 | A |
5451207 | Yock et al. | Sep 1995 | A |
5453091 | Taylor et al. | Sep 1995 | A |
5454788 | Walker et al. | Oct 1995 | A |
5454809 | Janssen | Oct 1995 | A |
5455029 | Hartman et al. | Oct 1995 | A |
5456682 | Edwards et al. | Oct 1995 | A |
5457042 | Hartman et al. | Oct 1995 | A |
5471982 | Edwards et al. | Dec 1995 | A |
5474530 | Passafaro et al. | Dec 1995 | A |
5478351 | Meade et al. | Dec 1995 | A |
5496311 | Abele et al. | Mar 1996 | A |
5496312 | Klicek et al. | Mar 1996 | A |
5498261 | Strul | Mar 1996 | A |
5505201 | Grill et al. | Apr 1996 | A |
5505730 | Edwards | Apr 1996 | A |
5507744 | Tay et al. | Apr 1996 | A |
5512051 | Wang et al. | Apr 1996 | A |
5522873 | Jackman et al. | Jun 1996 | A |
5531520 | Grimson et al. | Jul 1996 | A |
5540656 | Pflueger et al. | Jul 1996 | A |
5540679 | Fram et al. | Jul 1996 | A |
5540681 | Strul et al. | Jul 1996 | A |
5542917 | Nita et al. | Aug 1996 | A |
5545161 | Imran | Aug 1996 | A |
5562100 | Kittrell et al. | Oct 1996 | A |
5571122 | Kelly et al. | Nov 1996 | A |
5571151 | Gregory | Nov 1996 | A |
5573531 | Gregory et al. | Nov 1996 | A |
5573533 | Strul | Nov 1996 | A |
5584831 | McKay | Dec 1996 | A |
5584872 | Lafontaine et al. | Dec 1996 | A |
5588962 | Nicholas et al. | Dec 1996 | A |
5599346 | Edwards et al. | Feb 1997 | A |
5601526 | Chapelon et al. | Feb 1997 | A |
5609606 | O'Boyle et al. | Mar 1997 | A |
5613979 | Trotta et al. | Mar 1997 | A |
5626576 | Janssen | May 1997 | A |
5630837 | Crowley | May 1997 | A |
5637090 | McGee et al. | Jun 1997 | A |
5643255 | Organ | Jul 1997 | A |
5643297 | Nordgren et al. | Jul 1997 | A |
5647847 | Lafontaine et al. | Jul 1997 | A |
5649923 | Gregory et al. | Jul 1997 | A |
5651780 | Jackson et al. | Jul 1997 | A |
5653684 | Laptewicz et al. | Aug 1997 | A |
5662671 | Barbut et al. | Sep 1997 | A |
5665062 | Houser | Sep 1997 | A |
5665098 | Kelly et al. | Sep 1997 | A |
5666964 | Meilus | Sep 1997 | A |
5667490 | Keith et al. | Sep 1997 | A |
5672174 | Gough et al. | Sep 1997 | A |
5676693 | Lafontaine | Oct 1997 | A |
5678296 | Fleischhacker et al. | Oct 1997 | A |
5681282 | Eggers et al. | Oct 1997 | A |
RE35656 | Feinberg | Nov 1997 | E |
5687737 | Branham et al. | Nov 1997 | A |
5688266 | Edwards et al. | Nov 1997 | A |
5693015 | Walker et al. | Dec 1997 | A |
5693029 | Leonhardt et al. | Dec 1997 | A |
5693043 | Kittrell et al. | Dec 1997 | A |
5693082 | Warner et al. | Dec 1997 | A |
5695504 | Gifford et al. | Dec 1997 | A |
5697369 | Long, Jr. et al. | Dec 1997 | A |
5697909 | Eggers et al. | Dec 1997 | A |
5702386 | Stern et al. | Dec 1997 | A |
5702433 | Taylor et al. | Dec 1997 | A |
5706809 | Littmann et al. | Jan 1998 | A |
5713942 | Stern et al. | Feb 1998 | A |
5715819 | Svenson et al. | Feb 1998 | A |
5735846 | Panescu et al. | Apr 1998 | A |
5741214 | Ouchi et al. | Apr 1998 | A |
5741248 | Stern et al. | Apr 1998 | A |
5741249 | Moss et al. | Apr 1998 | A |
5743903 | Stern et al. | Apr 1998 | A |
5748347 | Erickson | May 1998 | A |
5749914 | Janssen | May 1998 | A |
5755682 | Knudson et al. | May 1998 | A |
5755715 | Stern et al. | May 1998 | A |
5755753 | Knowlton | May 1998 | A |
5769847 | Panescu et al. | Jun 1998 | A |
5769880 | Truckai et al. | Jun 1998 | A |
5775338 | Hastings | Jul 1998 | A |
5776174 | Van Tassel | Jul 1998 | A |
5779698 | Clayman et al. | Jul 1998 | A |
5782760 | Schaer | Jul 1998 | A |
5785702 | Murphy-Chutorian et al. | Jul 1998 | A |
5797849 | Vesely et al. | Aug 1998 | A |
5797903 | Swanson et al. | Aug 1998 | A |
5800484 | Gough et al. | Sep 1998 | A |
5800494 | Campbell et al. | Sep 1998 | A |
5807306 | Shapland et al. | Sep 1998 | A |
5810802 | Panescu et al. | Sep 1998 | A |
5810803 | Moss et al. | Sep 1998 | A |
5810810 | Tay et al. | Sep 1998 | A |
5817092 | Behl | Oct 1998 | A |
5817113 | Gifford et al. | Oct 1998 | A |
5817144 | Gregory et al. | Oct 1998 | A |
5823956 | Roth et al. | Oct 1998 | A |
5827203 | Nita et al. | Oct 1998 | A |
5827268 | Laufer | Oct 1998 | A |
5829447 | Stevens et al. | Nov 1998 | A |
5830213 | Panescu et al. | Nov 1998 | A |
5830222 | Makower | Nov 1998 | A |
5832228 | Holden et al. | Nov 1998 | A |
5833593 | Liprie | Nov 1998 | A |
5836874 | Swanson et al. | Nov 1998 | A |
5840076 | Swanson et al. | Nov 1998 | A |
5843016 | Lugnani et al. | Dec 1998 | A |
5846238 | Jackson et al. | Dec 1998 | A |
5846239 | Swanson et al. | Dec 1998 | A |
5846245 | McCarthy et al. | Dec 1998 | A |
5848969 | Panescu et al. | Dec 1998 | A |
5853411 | Whayne et al. | Dec 1998 | A |
5855614 | Stevens et al. | Jan 1999 | A |
5860974 | Abele | Jan 1999 | A |
5865801 | Houser | Feb 1999 | A |
5868735 | Lafontaine et al. | Feb 1999 | A |
5868736 | Swanson et al. | Feb 1999 | A |
5871483 | Jackson et al. | Feb 1999 | A |
5871524 | Knowlton et al. | Feb 1999 | A |
5875782 | Ferrari et al. | Mar 1999 | A |
5876369 | Houser | Mar 1999 | A |
5876374 | Alba et al. | Mar 1999 | A |
5876397 | Edelman et al. | Mar 1999 | A |
5879348 | Owens et al. | Mar 1999 | A |
5891114 | Chien et al. | Apr 1999 | A |
5891135 | Jackson et al. | Apr 1999 | A |
5891136 | McGee et al. | Apr 1999 | A |
5891138 | Tu et al. | Apr 1999 | A |
5895378 | Nita | Apr 1999 | A |
5897552 | Edwards et al. | Apr 1999 | A |
5902328 | Lafontaine et al. | May 1999 | A |
5904651 | Swanson et al. | May 1999 | A |
5904667 | Falwell et al. | May 1999 | A |
5904697 | Gifford et al. | May 1999 | A |
5904709 | Arndt et al. | May 1999 | A |
5906614 | Stern et al. | May 1999 | A |
5906623 | Peterson | May 1999 | A |
5906636 | Casscells et al. | May 1999 | A |
5916192 | Nita et al. | Jun 1999 | A |
5916227 | Keith et al. | Jun 1999 | A |
5916239 | Geddes et al. | Jun 1999 | A |
5919219 | Knowlton et al. | Jul 1999 | A |
5924424 | Stevens et al. | Jul 1999 | A |
5925038 | Panescu et al. | Jul 1999 | A |
5934284 | Plaia et al. | Aug 1999 | A |
5935063 | Nguyen | Aug 1999 | A |
5938670 | Keith et al. | Aug 1999 | A |
5947977 | Slepian et al. | Sep 1999 | A |
5948011 | Knowlton et al. | Sep 1999 | A |
5951494 | Wang et al. | Sep 1999 | A |
5951539 | Nita et al. | Sep 1999 | A |
5954717 | Behl et al. | Sep 1999 | A |
5957882 | Nita et al. | Sep 1999 | A |
5957941 | Ream et al. | Sep 1999 | A |
5957969 | Warner et al. | Sep 1999 | A |
5961513 | Swanson et al. | Oct 1999 | A |
5964757 | Ponzi et al. | Oct 1999 | A |
5967976 | Larsen et al. | Oct 1999 | A |
5967978 | Littmann et al. | Oct 1999 | A |
5967984 | Chu et al. | Oct 1999 | A |
5971975 | Mills et al. | Oct 1999 | A |
5972026 | Laufer et al. | Oct 1999 | A |
5980563 | Tu et al. | Nov 1999 | A |
5989208 | Nita et al. | Nov 1999 | A |
5989284 | Laufer | Nov 1999 | A |
5993462 | Pomeranz et al. | Nov 1999 | A |
5997497 | Nita et al. | Dec 1999 | A |
5999678 | Murphy-Chutorian et al. | Dec 1999 | A |
6004269 | Crowley et al. | Dec 1999 | A |
6004316 | Laufer et al. | Dec 1999 | A |
6007514 | Nita | Dec 1999 | A |
6010522 | Barbut et al. | Jan 2000 | A |
6013033 | Berger et al. | Jan 2000 | A |
6014590 | Whayne et al. | Jan 2000 | A |
6022309 | Celliers et al. | Feb 2000 | A |
6024740 | Lesh et al. | Feb 2000 | A |
6030611 | Gorecki et al. | Feb 2000 | A |
6032675 | Rubinsky et al. | Mar 2000 | A |
6033397 | Laufer et al. | Mar 2000 | A |
6033398 | Farley et al. | Mar 2000 | A |
6036687 | Laufer et al. | Mar 2000 | A |
6036689 | Tu et al. | Mar 2000 | A |
6041260 | Stern et al. | Mar 2000 | A |
6050994 | Sherman et al. | Apr 2000 | A |
6056744 | Edwards | May 2000 | A |
6056746 | Goble et al. | May 2000 | A |
6063085 | Tay et al. | May 2000 | A |
6066096 | Smith et al. | May 2000 | A |
6066139 | Ryan et al. | May 2000 | A |
6068638 | Makower | May 2000 | A |
6068653 | Lafontaine | May 2000 | A |
6071277 | Farley et al. | Jun 2000 | A |
6071278 | Panescu et al. | Jun 2000 | A |
6078839 | Carson | Jun 2000 | A |
6079414 | Roth | Jun 2000 | A |
6080171 | Keith et al. | Jun 2000 | A |
6081749 | Ingle et al. | Jun 2000 | A |
6086581 | Reynolds et al. | Jul 2000 | A |
6091995 | Ingle et al. | Jul 2000 | A |
6093166 | Knudson et al. | Jul 2000 | A |
6096021 | Helm et al. | Aug 2000 | A |
6099526 | Whayne et al. | Aug 2000 | A |
6102908 | Tu et al. | Aug 2000 | A |
6106477 | Miesel et al. | Aug 2000 | A |
6110187 | Donlon et al. | Aug 2000 | A |
6110192 | Ravenscroft et al. | Aug 2000 | A |
6114311 | Parmacek et al. | Sep 2000 | A |
6117101 | Diederich et al. | Sep 2000 | A |
6117128 | Gregory | Sep 2000 | A |
6120476 | Fung et al. | Sep 2000 | A |
6120516 | Selmon et al. | Sep 2000 | A |
6121775 | Pearlman | Sep 2000 | A |
6123679 | Lafaut et al. | Sep 2000 | A |
6123682 | Knudson et al. | Sep 2000 | A |
6123702 | Swanson et al. | Sep 2000 | A |
6123703 | Tu et al. | Sep 2000 | A |
6123718 | Tu et al. | Sep 2000 | A |
6129725 | Tu et al. | Oct 2000 | A |
6135997 | Laufer et al. | Oct 2000 | A |
6142991 | Schatzberger et al. | Nov 2000 | A |
6142993 | Whayne et al. | Nov 2000 | A |
6149647 | Tu et al. | Nov 2000 | A |
6152899 | Farley et al. | Nov 2000 | A |
6152912 | Jansen et al. | Nov 2000 | A |
6156046 | Passafaro et al. | Dec 2000 | A |
6158250 | Tibbals et al. | Dec 2000 | A |
6159187 | Park et al. | Dec 2000 | A |
6159225 | Makower | Dec 2000 | A |
6161048 | Sluijter et al. | Dec 2000 | A |
6162184 | Swanson et al. | Dec 2000 | A |
6165163 | Chien et al. | Dec 2000 | A |
6165172 | Farley et al. | Dec 2000 | A |
6165187 | Reger et al. | Dec 2000 | A |
6168594 | Lafontaine et al. | Jan 2001 | B1 |
6171321 | Gifford, III et al. | Jan 2001 | B1 |
6179832 | Jones et al. | Jan 2001 | B1 |
6179835 | Panescu et al. | Jan 2001 | B1 |
6179859 | Bates et al. | Jan 2001 | B1 |
6183468 | Swanson et al. | Feb 2001 | B1 |
6183486 | Snow et al. | Feb 2001 | B1 |
6190379 | Heuser et al. | Feb 2001 | B1 |
6191862 | Swanson et al. | Feb 2001 | B1 |
6197021 | Panescu et al. | Mar 2001 | B1 |
6200266 | Shokrollahi et al. | Mar 2001 | B1 |
6203537 | Adrian | Mar 2001 | B1 |
6203561 | Ramee et al. | Mar 2001 | B1 |
6210406 | Webster | Apr 2001 | B1 |
6211247 | Goodman | Apr 2001 | B1 |
6217576 | Tu et al. | Apr 2001 | B1 |
6219577 | Brown, III et al. | Apr 2001 | B1 |
6228076 | Winston et al. | May 2001 | B1 |
6228109 | Tu et al. | May 2001 | B1 |
6231516 | Keilman et al. | May 2001 | B1 |
6231587 | Makower | May 2001 | B1 |
6235044 | Root et al. | May 2001 | B1 |
6236883 | Ciaccio et al. | May 2001 | B1 |
6237605 | Vaska et al. | May 2001 | B1 |
6238389 | Paddock et al. | May 2001 | B1 |
6238392 | Long | May 2001 | B1 |
6241666 | Pomeranz et al. | Jun 2001 | B1 |
6241753 | Knowlton | Jun 2001 | B1 |
6245020 | Moore et al. | Jun 2001 | B1 |
6245045 | Stratienko | Jun 2001 | B1 |
6248126 | Lesser et al. | Jun 2001 | B1 |
6251128 | Knopp et al. | Jun 2001 | B1 |
6251129 | Dobak, III | Jun 2001 | B1 |
6258087 | Edwards et al. | Jul 2001 | B1 |
6273886 | Edwards et al. | Aug 2001 | B1 |
6280466 | Kugler et al. | Aug 2001 | B1 |
6283935 | Laufer et al. | Sep 2001 | B1 |
6283959 | Lalonde et al. | Sep 2001 | B1 |
6284743 | Parmacek et al. | Sep 2001 | B1 |
6287323 | Hammerslag | Sep 2001 | B1 |
6290696 | Lafontaine | Sep 2001 | B1 |
6292695 | Webster, Jr. et al. | Sep 2001 | B1 |
6293942 | Goble et al. | Sep 2001 | B1 |
6293943 | Panescu et al. | Sep 2001 | B1 |
6296619 | Brisken et al. | Oct 2001 | B1 |
6298256 | Meyer | Oct 2001 | B1 |
6299379 | Lewis | Oct 2001 | B1 |
6299623 | Wulfman | Oct 2001 | B1 |
6309379 | Willard et al. | Oct 2001 | B1 |
6309399 | Barbut et al. | Oct 2001 | B1 |
6311090 | Knowlton | Oct 2001 | B1 |
6317615 | KenKnight et al. | Nov 2001 | B1 |
6319242 | Patterson et al. | Nov 2001 | B1 |
6319251 | Tu et al. | Nov 2001 | B1 |
6322559 | Daulton et al. | Nov 2001 | B1 |
6325797 | Stewart et al. | Dec 2001 | B1 |
6325799 | Goble | Dec 2001 | B1 |
6328699 | Eigler et al. | Dec 2001 | B1 |
6346074 | Roth | Feb 2002 | B1 |
6346104 | Daly et al. | Feb 2002 | B2 |
6350248 | Knudson et al. | Feb 2002 | B1 |
6350276 | Knowlton | Feb 2002 | B1 |
6353751 | Swanson et al. | Mar 2002 | B1 |
6355029 | Joye et al. | Mar 2002 | B1 |
6357447 | Swanson et al. | Mar 2002 | B1 |
6361519 | Knudson et al. | Mar 2002 | B1 |
6364840 | Crowley | Apr 2002 | B1 |
6371965 | Gifford, III et al. | Apr 2002 | B2 |
6375668 | Gifford et al. | Apr 2002 | B1 |
6377854 | Knowlton | Apr 2002 | B1 |
6377855 | Knowlton | Apr 2002 | B1 |
6379352 | Reynolds et al. | Apr 2002 | B1 |
6379373 | Sawhney et al. | Apr 2002 | B1 |
6381497 | Knowlton | Apr 2002 | B1 |
6381498 | Knowlton | Apr 2002 | B1 |
6383151 | Diederich et al. | May 2002 | B1 |
6387105 | Gifford, III et al. | May 2002 | B1 |
6387380 | Knowlton | May 2002 | B1 |
6389311 | Whayne et al. | May 2002 | B1 |
6389314 | Feiring | May 2002 | B2 |
6391024 | Sun et al. | May 2002 | B1 |
6394096 | Constantz | May 2002 | B1 |
6394956 | Chandrasekaran et al. | May 2002 | B1 |
6398780 | Farley et al. | Jun 2002 | B1 |
6398782 | Pecor et al. | Jun 2002 | B1 |
6398792 | O'Connor | Jun 2002 | B1 |
6401720 | Stevens et al. | Jun 2002 | B1 |
6402719 | Ponzi et al. | Jun 2002 | B1 |
6405090 | Knowlton | Jun 2002 | B1 |
6409723 | Edwards | Jun 2002 | B1 |
6413255 | Stern | Jul 2002 | B1 |
6421559 | Pearlman | Jul 2002 | B1 |
6423057 | He et al. | Jul 2002 | B1 |
6425867 | Vaezy et al. | Jul 2002 | B1 |
6425912 | Knowlton | Jul 2002 | B1 |
6427118 | Suzuki | Jul 2002 | B1 |
6428534 | Joye et al. | Aug 2002 | B1 |
6428536 | Panescu et al. | Aug 2002 | B2 |
6430446 | Knowlton | Aug 2002 | B1 |
6432102 | Joye et al. | Aug 2002 | B2 |
6436056 | Wang et al. | Aug 2002 | B1 |
6438424 | Knowlton | Aug 2002 | B1 |
6440125 | Rentrop | Aug 2002 | B1 |
6442413 | Silver | Aug 2002 | B1 |
6443965 | Gifford, III et al. | Sep 2002 | B1 |
6445939 | Swanson et al. | Sep 2002 | B1 |
6447505 | McGovern et al. | Sep 2002 | B2 |
6447509 | Bonnet et al. | Sep 2002 | B1 |
6451034 | Gifford, III et al. | Sep 2002 | B1 |
6451044 | Naghavi et al. | Sep 2002 | B1 |
6453202 | Knowlton | Sep 2002 | B1 |
6454737 | Nita et al. | Sep 2002 | B1 |
6454757 | Nita et al. | Sep 2002 | B1 |
6454775 | Demarais et al. | Sep 2002 | B1 |
6458098 | Kanesaka | Oct 2002 | B1 |
6461378 | Knowlton | Oct 2002 | B1 |
6468276 | McKay | Oct 2002 | B1 |
6468297 | Williams et al. | Oct 2002 | B1 |
6470216 | Knowlton | Oct 2002 | B1 |
6470219 | Edwards et al. | Oct 2002 | B1 |
6471696 | Berube et al. | Oct 2002 | B1 |
6475213 | Whayne et al. | Nov 2002 | B1 |
6475215 | Tanrisever | Nov 2002 | B1 |
6475238 | Fedida et al. | Nov 2002 | B1 |
6477426 | Fenn et al. | Nov 2002 | B1 |
6480745 | Nelson et al. | Nov 2002 | B2 |
6481704 | Koster et al. | Nov 2002 | B1 |
6482202 | Goble et al. | Nov 2002 | B1 |
6484052 | Visuri et al. | Nov 2002 | B1 |
6485489 | Teirstein et al. | Nov 2002 | B2 |
6488679 | Swanson et al. | Dec 2002 | B1 |
6489307 | Phillips et al. | Dec 2002 | B1 |
6491705 | Gifford, III et al. | Dec 2002 | B2 |
6494891 | Cornish et al. | Dec 2002 | B1 |
6497711 | Plaia et al. | Dec 2002 | B1 |
6500172 | Panescu et al. | Dec 2002 | B1 |
6500174 | Maguire et al. | Dec 2002 | B1 |
6508765 | Suorsa et al. | Jan 2003 | B2 |
6508804 | Sarge et al. | Jan 2003 | B2 |
6508815 | Strul et al. | Jan 2003 | B1 |
6511478 | Burnside et al. | Jan 2003 | B1 |
6511496 | Huter et al. | Jan 2003 | B1 |
6511500 | Rahme | Jan 2003 | B1 |
6514236 | Stratienko | Feb 2003 | B1 |
6514245 | Williams et al. | Feb 2003 | B1 |
6514248 | Eggers et al. | Feb 2003 | B1 |
6517534 | McGovern et al. | Feb 2003 | B1 |
6517572 | Kugler et al. | Feb 2003 | B2 |
6522913 | Panescu et al. | Feb 2003 | B2 |
6522926 | Kieval et al. | Feb 2003 | B1 |
6524299 | Tran et al. | Feb 2003 | B1 |
6527765 | Kelman et al. | Mar 2003 | B2 |
6527769 | Langberg et al. | Mar 2003 | B2 |
6540761 | Houser | Apr 2003 | B2 |
6542781 | Koblish et al. | Apr 2003 | B1 |
6544780 | Wang | Apr 2003 | B1 |
6546272 | MacKinnon et al. | Apr 2003 | B1 |
6547788 | Maguire et al. | Apr 2003 | B1 |
6549800 | Atalar et al. | Apr 2003 | B1 |
6552796 | Magnin et al. | Apr 2003 | B2 |
6554780 | Sampson et al. | Apr 2003 | B1 |
6558381 | Ingle et al. | May 2003 | B2 |
6558382 | Jahns et al. | May 2003 | B2 |
6564096 | Mest | May 2003 | B2 |
6565582 | Gifford, III et al. | May 2003 | B2 |
6569109 | Sakurai et al. | May 2003 | B2 |
6569177 | Dillard et al. | May 2003 | B1 |
6570659 | Schmitt | May 2003 | B2 |
6572551 | Smith et al. | Jun 2003 | B1 |
6572612 | Stewart et al. | Jun 2003 | B2 |
6577902 | Laufer et al. | Jun 2003 | B1 |
6579308 | Jansen et al. | Jun 2003 | B1 |
6579311 | Makower | Jun 2003 | B1 |
6582423 | Thapliyal et al. | Jun 2003 | B1 |
6589238 | Edwards et al. | Jul 2003 | B2 |
6592526 | Lenker | Jul 2003 | B1 |
6592567 | Levin et al. | Jul 2003 | B1 |
6595959 | Stratienko | Jul 2003 | B1 |
6600956 | Maschino et al. | Jul 2003 | B2 |
6602242 | Fung et al. | Aug 2003 | B1 |
6602246 | Joye et al. | Aug 2003 | B1 |
6605056 | Eidenschink et al. | Aug 2003 | B2 |
6605084 | Acker et al. | Aug 2003 | B2 |
6623452 | Chien et al. | Sep 2003 | B2 |
6623453 | Guibert et al. | Sep 2003 | B1 |
6632193 | Davison et al. | Oct 2003 | B1 |
6632196 | Houser | Oct 2003 | B1 |
6645223 | Boyle et al. | Nov 2003 | B2 |
6648854 | Patterson et al. | Nov 2003 | B1 |
6648878 | Lafontaine | Nov 2003 | B2 |
6648879 | Holland et al. | Nov 2003 | B2 |
6651672 | Roth | Nov 2003 | B2 |
6652513 | Panescu et al. | Nov 2003 | B2 |
6652515 | Maguire et al. | Nov 2003 | B1 |
6656136 | Weng et al. | Dec 2003 | B1 |
6658279 | Swanson et al. | Dec 2003 | B2 |
6659981 | Stewart et al. | Dec 2003 | B2 |
6666858 | Lafontaine | Dec 2003 | B2 |
6666863 | Wentzel et al. | Dec 2003 | B2 |
6669655 | Acker et al. | Dec 2003 | B1 |
6669692 | Nelson et al. | Dec 2003 | B1 |
6673040 | Samson et al. | Jan 2004 | B1 |
6673064 | Rentrop | Jan 2004 | B1 |
6673066 | Werneth | Jan 2004 | B2 |
6673090 | Root et al. | Jan 2004 | B2 |
6673101 | Fitzgerald et al. | Jan 2004 | B1 |
6673290 | Whayne et al. | Jan 2004 | B1 |
6676678 | Gifford, III et al. | Jan 2004 | B2 |
6679268 | Stevens et al. | Jan 2004 | B2 |
6681773 | Murphy et al. | Jan 2004 | B2 |
6682541 | Gifford, III et al. | Jan 2004 | B1 |
6684098 | Oshio et al. | Jan 2004 | B2 |
6685732 | Kramer | Feb 2004 | B2 |
6685733 | Dae et al. | Feb 2004 | B1 |
6689086 | Nita et al. | Feb 2004 | B1 |
6689148 | Sawhney et al. | Feb 2004 | B2 |
6690181 | Dowdeswell et al. | Feb 2004 | B1 |
6692490 | Edwards | Feb 2004 | B1 |
6695830 | Vigil et al. | Feb 2004 | B2 |
6695857 | Gifford, III et al. | Feb 2004 | B2 |
6699241 | Rappaport et al. | Mar 2004 | B2 |
6699257 | Gifford, III et al. | Mar 2004 | B2 |
6702748 | Nita et al. | Mar 2004 | B1 |
6702811 | Stewart et al. | Mar 2004 | B2 |
6706010 | Miki et al. | Mar 2004 | B1 |
6706011 | Murphy-Chutorian et al. | Mar 2004 | B1 |
6706037 | Zvuloni et al. | Mar 2004 | B2 |
6709431 | Lafontaine | Mar 2004 | B2 |
6711429 | Gilboa et al. | Mar 2004 | B1 |
6712815 | Sampson et al. | Mar 2004 | B2 |
6714822 | King et al. | Mar 2004 | B2 |
6716184 | Vaezy et al. | Apr 2004 | B2 |
6720350 | Kunz et al. | Apr 2004 | B2 |
6723043 | Kleeman et al. | Apr 2004 | B2 |
6723064 | Babaev | Apr 2004 | B2 |
6736811 | Panescu et al. | May 2004 | B2 |
6743184 | Sampson et al. | Jun 2004 | B2 |
6746401 | Panescu | Jun 2004 | B2 |
6746464 | Makower | Jun 2004 | B1 |
6746474 | Saadat | Jun 2004 | B2 |
6748953 | Sherry et al. | Jun 2004 | B2 |
6749607 | Edwards et al. | Jun 2004 | B2 |
6752805 | Maguire et al. | Jun 2004 | B2 |
6760616 | Hoey et al. | Jul 2004 | B2 |
6763261 | Casscells, III et al. | Jul 2004 | B2 |
6764501 | Ganz | Jul 2004 | B2 |
6769433 | Zikorus et al. | Aug 2004 | B2 |
6770070 | Balbierz | Aug 2004 | B1 |
6771996 | Bowe et al. | Aug 2004 | B2 |
6773433 | Stewart et al. | Aug 2004 | B2 |
6786900 | Joye et al. | Sep 2004 | B2 |
6786901 | Joye et al. | Sep 2004 | B2 |
6786904 | Döscher et al. | Sep 2004 | B2 |
6788977 | Fenn et al. | Sep 2004 | B2 |
6790206 | Panescu | Sep 2004 | B2 |
6790222 | Kugler et al. | Sep 2004 | B2 |
6796981 | Wham et al. | Sep 2004 | B2 |
6797933 | Mendis et al. | Sep 2004 | B1 |
6797960 | Spartiotis et al. | Sep 2004 | B1 |
6800075 | Mische et al. | Oct 2004 | B2 |
6802857 | Walsh et al. | Oct 2004 | B1 |
6807444 | Tu et al. | Oct 2004 | B2 |
6811550 | Holland et al. | Nov 2004 | B2 |
6813520 | Sampson et al. | Nov 2004 | B2 |
6814730 | Li | Nov 2004 | B2 |
6814733 | Leatham et al. | Nov 2004 | B2 |
6823205 | Jara | Nov 2004 | B1 |
6824516 | Batten et al. | Nov 2004 | B2 |
6827726 | Parodi | Dec 2004 | B2 |
6827926 | Robinson et al. | Dec 2004 | B2 |
6829497 | Mogul | Dec 2004 | B2 |
6830568 | Kesten et al. | Dec 2004 | B1 |
6837886 | Collins et al. | Jan 2005 | B2 |
6837888 | Ciarrocca et al. | Jan 2005 | B2 |
6845267 | Harrison et al. | Jan 2005 | B2 |
6847848 | Sterzer | Jan 2005 | B2 |
6849073 | Hoey et al. | Feb 2005 | B2 |
6849075 | Bertolero et al. | Feb 2005 | B2 |
6853425 | Kim et al. | Feb 2005 | B2 |
6855123 | Nita | Feb 2005 | B2 |
6855143 | Davison | Feb 2005 | B2 |
6869431 | Maguire et al. | Mar 2005 | B2 |
6872183 | Sampson et al. | Mar 2005 | B2 |
6884260 | Kugler et al. | Apr 2005 | B2 |
6889694 | Hooven | May 2005 | B2 |
6893436 | Woodard et al. | May 2005 | B2 |
6895077 | Karellas et al. | May 2005 | B2 |
6895265 | Silver | May 2005 | B2 |
6898454 | Atalar et al. | May 2005 | B2 |
6899711 | Stewart et al. | May 2005 | B2 |
6899718 | Gifford, III et al. | May 2005 | B2 |
6905494 | Yon et al. | Jun 2005 | B2 |
6908462 | Joye et al. | Jun 2005 | B2 |
6909009 | Koridze | Jun 2005 | B2 |
6911026 | Hall et al. | Jun 2005 | B1 |
6915806 | Pacek et al. | Jul 2005 | B2 |
6923805 | LaFontaine et al. | Aug 2005 | B1 |
6923808 | Taimisto | Aug 2005 | B2 |
6926246 | Ginggen | Aug 2005 | B2 |
6926713 | Rioux et al. | Aug 2005 | B2 |
6926716 | Baker et al. | Aug 2005 | B2 |
6929009 | Makower et al. | Aug 2005 | B2 |
6929632 | Nita et al. | Aug 2005 | B2 |
6929639 | Lafontaine | Aug 2005 | B2 |
6932776 | Carr | Aug 2005 | B2 |
6936047 | Nasab et al. | Aug 2005 | B2 |
6942620 | Nita et al. | Sep 2005 | B2 |
6942657 | Sinofsky et al. | Sep 2005 | B2 |
6942677 | Nita et al. | Sep 2005 | B2 |
6942692 | Landau et al. | Sep 2005 | B2 |
6949097 | Stewart et al. | Sep 2005 | B2 |
6949121 | Laguna | Sep 2005 | B1 |
6952615 | Satake | Oct 2005 | B2 |
6953425 | Brister | Oct 2005 | B2 |
6955174 | Joye et al. | Oct 2005 | B2 |
6955175 | Stevens et al. | Oct 2005 | B2 |
6959711 | Murphy et al. | Nov 2005 | B2 |
6960207 | Vanney et al. | Nov 2005 | B2 |
6962584 | Stone et al. | Nov 2005 | B1 |
6964660 | Maguire et al. | Nov 2005 | B2 |
6966908 | Maguire et al. | Nov 2005 | B2 |
6972015 | Joye et al. | Dec 2005 | B2 |
6972024 | Kilpatrick et al. | Dec 2005 | B1 |
6974456 | Edwards et al. | Dec 2005 | B2 |
6978174 | Gelfand et al. | Dec 2005 | B2 |
6979329 | Burnside et al. | Dec 2005 | B2 |
6979420 | Weber | Dec 2005 | B2 |
6984238 | Gifford, III et al. | Jan 2006 | B2 |
6985774 | Kieval et al. | Jan 2006 | B2 |
6986739 | Warren et al. | Jan 2006 | B2 |
6989009 | Lafontaine | Jan 2006 | B2 |
6989010 | Francischelli et al. | Jan 2006 | B2 |
6991617 | Hektner et al. | Jan 2006 | B2 |
7001378 | Yon et al. | Feb 2006 | B2 |
7006858 | Silver et al. | Feb 2006 | B2 |
7022105 | Edwards | Apr 2006 | B1 |
7022120 | Lafontaine | Apr 2006 | B2 |
7025767 | Schaefer et al. | Apr 2006 | B2 |
7033322 | Silver | Apr 2006 | B2 |
7033372 | Cahalan | Apr 2006 | B1 |
7041098 | Farley et al. | May 2006 | B2 |
7050848 | Hoey et al. | May 2006 | B2 |
7063670 | Sampson et al. | Jun 2006 | B2 |
7063679 | Maguire et al. | Jun 2006 | B2 |
7063719 | Jansen et al. | Jun 2006 | B2 |
7066895 | Podany | Jun 2006 | B2 |
7066900 | Botto et al. | Jun 2006 | B2 |
7066904 | Rosenthal et al. | Jun 2006 | B2 |
7072720 | Puskas | Jul 2006 | B2 |
7074217 | Strul et al. | Jul 2006 | B2 |
7081112 | Joye et al. | Jul 2006 | B2 |
7081114 | Rashidi | Jul 2006 | B2 |
7083614 | Fjield et al. | Aug 2006 | B2 |
7084276 | Vu et al. | Aug 2006 | B2 |
7087026 | Callister et al. | Aug 2006 | B2 |
7087051 | Bourne et al. | Aug 2006 | B2 |
7087052 | Sampson et al. | Aug 2006 | B2 |
7087053 | Vanney | Aug 2006 | B2 |
7089065 | Westlund et al. | Aug 2006 | B2 |
7097641 | Arless et al. | Aug 2006 | B1 |
7100614 | Stevens et al. | Sep 2006 | B2 |
7101368 | Lafontaine | Sep 2006 | B2 |
7104983 | Grasso, III et al. | Sep 2006 | B2 |
7104987 | Biggs et al. | Sep 2006 | B2 |
7108715 | Lawrence-Brown et al. | Sep 2006 | B2 |
7112196 | Brosch et al. | Sep 2006 | B2 |
7112198 | Satake | Sep 2006 | B2 |
7112211 | Gifford, III et al. | Sep 2006 | B2 |
7122019 | Kesten et al. | Oct 2006 | B1 |
7122033 | Wood | Oct 2006 | B2 |
7134438 | Makower et al. | Nov 2006 | B2 |
7137963 | Nita et al. | Nov 2006 | B2 |
7137980 | Buysse et al. | Nov 2006 | B2 |
7153315 | Miller | Dec 2006 | B2 |
7155271 | Halperin et al. | Dec 2006 | B2 |
7157491 | Mewshaw et al. | Jan 2007 | B2 |
7157492 | Mewshaw et al. | Jan 2007 | B2 |
7158832 | Kieval et al. | Jan 2007 | B2 |
7160296 | Pearson et al. | Jan 2007 | B2 |
7162303 | Levin et al. | Jan 2007 | B2 |
7165551 | Edwards et al. | Jan 2007 | B2 |
7169144 | Hoey et al. | Jan 2007 | B2 |
7172589 | Lafontaine | Feb 2007 | B2 |
7172610 | Heitzmann et al. | Feb 2007 | B2 |
7181261 | Silver et al. | Feb 2007 | B2 |
7184811 | Phan et al. | Feb 2007 | B2 |
7184827 | Edwards | Feb 2007 | B1 |
7189227 | Lafontaine | Mar 2007 | B2 |
7192427 | Chapelon et al. | Mar 2007 | B2 |
7192586 | Bander | Mar 2007 | B2 |
7197354 | Sobe | Mar 2007 | B2 |
7198632 | Lim et al. | Apr 2007 | B2 |
7200445 | Dalbec et al. | Apr 2007 | B1 |
7201749 | Govari et al. | Apr 2007 | B2 |
7203537 | Mower | Apr 2007 | B2 |
7214234 | Rapacki et al. | May 2007 | B2 |
7220233 | Nita et al. | May 2007 | B2 |
7220239 | Wilson et al. | May 2007 | B2 |
7220257 | Lafontaine | May 2007 | B1 |
7220270 | Sawhney et al. | May 2007 | B2 |
7232458 | Saadat | Jun 2007 | B2 |
7232459 | Greenberg et al. | Jun 2007 | B2 |
7238184 | Megerman et al. | Jul 2007 | B2 |
7241273 | Maguire et al. | Jul 2007 | B2 |
7241736 | Hunter et al. | Jul 2007 | B2 |
7247141 | Makin et al. | Jul 2007 | B2 |
7250041 | Chiu et al. | Jul 2007 | B2 |
7250440 | Mewshaw et al. | Jul 2007 | B2 |
7252664 | Nasab et al. | Aug 2007 | B2 |
7252679 | Fischell et al. | Aug 2007 | B2 |
7264619 | Venturelli | Sep 2007 | B2 |
7279600 | Mewshaw et al. | Oct 2007 | B2 |
7280863 | Shachar | Oct 2007 | B2 |
7282213 | Schroeder et al. | Oct 2007 | B2 |
7285119 | Stewart et al. | Oct 2007 | B2 |
7285120 | Im et al. | Oct 2007 | B2 |
7288089 | Yon et al. | Oct 2007 | B2 |
7288096 | Chin | Oct 2007 | B2 |
7291146 | Steinke et al. | Nov 2007 | B2 |
7293562 | Malecki et al. | Nov 2007 | B2 |
7294125 | Phalen et al. | Nov 2007 | B2 |
7294126 | Sampson et al. | Nov 2007 | B2 |
7294127 | Leung et al. | Nov 2007 | B2 |
7297131 | Nita | Nov 2007 | B2 |
7297475 | Koiwai et al. | Nov 2007 | B2 |
7300433 | Lane et al. | Nov 2007 | B2 |
7301108 | Egitto et al. | Nov 2007 | B2 |
7310150 | Guillermo et al. | Dec 2007 | B2 |
7313430 | Urquhart et al. | Dec 2007 | B2 |
7314480 | Eidenschink et al. | Jan 2008 | B2 |
7314483 | Landau et al. | Jan 2008 | B2 |
7317077 | Averback et al. | Jan 2008 | B2 |
7323006 | Andreas et al. | Jan 2008 | B2 |
7326206 | Paul et al. | Feb 2008 | B2 |
7326226 | Root et al. | Feb 2008 | B2 |
7326235 | Edwards | Feb 2008 | B2 |
7326237 | DePalma et al. | Feb 2008 | B2 |
7329236 | Kesten et al. | Feb 2008 | B2 |
7335180 | Nita et al. | Feb 2008 | B2 |
7335192 | Keren et al. | Feb 2008 | B2 |
7338467 | Lutter | Mar 2008 | B2 |
7341570 | Keren et al. | Mar 2008 | B2 |
7343195 | Strommer et al. | Mar 2008 | B2 |
7347857 | Anderson et al. | Mar 2008 | B2 |
7348003 | Salcedo et al. | Mar 2008 | B2 |
7352593 | Zeng et al. | Apr 2008 | B2 |
7354927 | Vu | Apr 2008 | B2 |
7359732 | Kim et al. | Apr 2008 | B2 |
7361341 | Salcedo et al. | Apr 2008 | B2 |
7364566 | Elkins et al. | Apr 2008 | B2 |
7367970 | Govari et al. | May 2008 | B2 |
7367975 | Malecki et al. | May 2008 | B2 |
7371231 | Rioux et al. | May 2008 | B2 |
7387126 | Cox et al. | Jun 2008 | B2 |
7393338 | Nita | Jul 2008 | B2 |
7396355 | Goldman et al. | Jul 2008 | B2 |
7402151 | Rosenman et al. | Jul 2008 | B2 |
7402312 | Rosen et al. | Jul 2008 | B2 |
7404824 | Webler et al. | Jul 2008 | B1 |
7406970 | Zikorus et al. | Aug 2008 | B2 |
7407502 | Strul et al. | Aug 2008 | B2 |
7407506 | Makower | Aug 2008 | B2 |
7407671 | McBride et al. | Aug 2008 | B2 |
7408021 | Averback et al. | Aug 2008 | B2 |
7410486 | Fuimaono et al. | Aug 2008 | B2 |
7413556 | Zhang et al. | Aug 2008 | B2 |
7425212 | Danek et al. | Sep 2008 | B1 |
7426409 | Casscells, III et al. | Sep 2008 | B2 |
7435248 | Taimisto et al. | Oct 2008 | B2 |
7447453 | Kim et al. | Nov 2008 | B2 |
7449018 | Kramer | Nov 2008 | B2 |
7452538 | Ni et al. | Nov 2008 | B2 |
7473890 | Grier et al. | Jan 2009 | B2 |
7476384 | Ni et al. | Jan 2009 | B2 |
7479157 | Weber et al. | Jan 2009 | B2 |
7481803 | Kesten et al. | Jan 2009 | B2 |
7485104 | Kieval | Feb 2009 | B2 |
7486805 | Krattiger | Feb 2009 | B2 |
7487780 | Hooven | Feb 2009 | B2 |
7493154 | Bonner et al. | Feb 2009 | B2 |
7494485 | Beck et al. | Feb 2009 | B2 |
7494486 | Mische et al. | Feb 2009 | B2 |
7494488 | Weber | Feb 2009 | B2 |
7494661 | Sanders | Feb 2009 | B2 |
7495439 | Wiggins | Feb 2009 | B2 |
7497858 | Chapelon et al. | Mar 2009 | B2 |
7499745 | Littrup et al. | Mar 2009 | B2 |
7500985 | Saadat | Mar 2009 | B2 |
7505812 | Eggers et al. | Mar 2009 | B1 |
7505816 | Schmeling et al. | Mar 2009 | B2 |
7507233 | Littrup et al. | Mar 2009 | B2 |
7507235 | Keogh et al. | Mar 2009 | B2 |
7511494 | Wedeen | Mar 2009 | B2 |
7512445 | Truckai et al. | Mar 2009 | B2 |
7527643 | Case et al. | May 2009 | B2 |
7529589 | Williams et al. | May 2009 | B2 |
7540852 | Nita et al. | Jun 2009 | B2 |
7540870 | Babaev | Jun 2009 | B2 |
RE40863 | Tay et al. | Jul 2009 | E |
7556624 | Laufer et al. | Jul 2009 | B2 |
7558625 | Levin et al. | Jul 2009 | B2 |
7563247 | Maguire et al. | Jul 2009 | B2 |
7566319 | McAuley et al. | Jul 2009 | B2 |
7569052 | Phan et al. | Aug 2009 | B2 |
7582111 | Krolik et al. | Sep 2009 | B2 |
7584004 | Caparso et al. | Sep 2009 | B2 |
7585835 | Hill et al. | Sep 2009 | B2 |
7591996 | Hwang et al. | Sep 2009 | B2 |
7597704 | Frazier et al. | Oct 2009 | B2 |
7598228 | Hattori et al. | Oct 2009 | B2 |
7599730 | Hunter et al. | Oct 2009 | B2 |
7603166 | Casscells, III et al. | Oct 2009 | B2 |
7604608 | Nita et al. | Oct 2009 | B2 |
7604633 | Truckai et al. | Oct 2009 | B2 |
7615015 | Coleman | Nov 2009 | B2 |
7615072 | Rust et al. | Nov 2009 | B2 |
7617005 | Demarais et al. | Nov 2009 | B2 |
7620451 | Demarais et al. | Nov 2009 | B2 |
7621902 | Nita et al. | Nov 2009 | B2 |
7621929 | Nita et al. | Nov 2009 | B2 |
7626015 | Feinstein et al. | Dec 2009 | B2 |
7626235 | Kinoshita | Dec 2009 | B2 |
7632268 | Edwards et al. | Dec 2009 | B2 |
7632845 | Vu et al. | Dec 2009 | B2 |
7635383 | Gumm | Dec 2009 | B2 |
7640046 | Pastore et al. | Dec 2009 | B2 |
7641633 | Laufer et al. | Jan 2010 | B2 |
7641679 | Joye et al. | Jan 2010 | B2 |
7646544 | Batchko et al. | Jan 2010 | B2 |
7647115 | Levin et al. | Jan 2010 | B2 |
7653438 | Deem et al. | Jan 2010 | B2 |
7655006 | Sauvageau et al. | Feb 2010 | B2 |
7662114 | Seip et al. | Feb 2010 | B2 |
7664548 | Amurthur et al. | Feb 2010 | B2 |
7670279 | Gertner | Mar 2010 | B2 |
7670335 | Keidar | Mar 2010 | B2 |
7671084 | Mewshaw et al. | Mar 2010 | B2 |
7678104 | Keidar | Mar 2010 | B2 |
7678106 | Lee | Mar 2010 | B2 |
7678108 | Chrisitian et al. | Mar 2010 | B2 |
7686841 | Eidenschink et al. | Mar 2010 | B2 |
7691080 | Seward et al. | Apr 2010 | B2 |
7699809 | Urmey | Apr 2010 | B2 |
7706882 | Francischelli et al. | Apr 2010 | B2 |
7715912 | Rezai et al. | May 2010 | B2 |
7717853 | Nita | May 2010 | B2 |
7717909 | Strul et al. | May 2010 | B2 |
7717948 | Demarais et al. | May 2010 | B2 |
7722539 | Carter et al. | May 2010 | B2 |
7725157 | Dumoulin et al. | May 2010 | B2 |
7727178 | Wilson et al. | Jun 2010 | B2 |
7736317 | Stephens et al. | Jun 2010 | B2 |
7736360 | Mody et al. | Jun 2010 | B2 |
7736362 | Eberl et al. | Jun 2010 | B2 |
7738952 | Yun et al. | Jun 2010 | B2 |
7740629 | Anderson et al. | Jun 2010 | B2 |
7741299 | Feinstein et al. | Jun 2010 | B2 |
7742795 | Stone et al. | Jun 2010 | B2 |
7744594 | Yamazaki et al. | Jun 2010 | B2 |
7753907 | DiMatteo et al. | Jul 2010 | B2 |
7756583 | Demarais et al. | Jul 2010 | B2 |
7758510 | Nita et al. | Jul 2010 | B2 |
7758520 | Griffin et al. | Jul 2010 | B2 |
7759315 | Cuzzocrea et al. | Jul 2010 | B2 |
7766833 | Lee et al. | Aug 2010 | B2 |
7766878 | Tremaglio, Jr. et al. | Aug 2010 | B2 |
7766892 | Keren et al. | Aug 2010 | B2 |
7767844 | Lee et al. | Aug 2010 | B2 |
7769427 | Shachar | Aug 2010 | B2 |
7771372 | Wilson | Aug 2010 | B2 |
7771421 | Stewart et al. | Aug 2010 | B2 |
7776967 | Perry et al. | Aug 2010 | B2 |
7777486 | Hargreaves et al. | Aug 2010 | B2 |
7780660 | Bourne et al. | Aug 2010 | B2 |
7789876 | Zikorus et al. | Sep 2010 | B2 |
7792568 | Zhong et al. | Sep 2010 | B2 |
7799021 | Leung et al. | Sep 2010 | B2 |
7803168 | Gifford et al. | Sep 2010 | B2 |
7806871 | Li et al. | Oct 2010 | B2 |
7811265 | Hering et al. | Oct 2010 | B2 |
7811281 | Rentrop | Oct 2010 | B1 |
7811313 | Mon et al. | Oct 2010 | B2 |
7816511 | Kawashima et al. | Oct 2010 | B2 |
7818053 | Kassab | Oct 2010 | B2 |
7819866 | Bednarek | Oct 2010 | B2 |
7822460 | Halperin et al. | Oct 2010 | B2 |
7828837 | Khoury | Nov 2010 | B2 |
7832407 | Gertner | Nov 2010 | B2 |
7833220 | Mon et al. | Nov 2010 | B2 |
7837676 | Sinelnikov et al. | Nov 2010 | B2 |
7837720 | Mon | Nov 2010 | B2 |
7841978 | Gertner | Nov 2010 | B2 |
7846157 | Kozel | Dec 2010 | B2 |
7846160 | Payne et al. | Dec 2010 | B2 |
7846172 | Makower | Dec 2010 | B2 |
7849860 | Makower et al. | Dec 2010 | B2 |
7850685 | Kunis et al. | Dec 2010 | B2 |
7853333 | Demarais | Dec 2010 | B2 |
7854734 | Biggs et al. | Dec 2010 | B2 |
7857756 | Warren et al. | Dec 2010 | B2 |
7862565 | Eder et al. | Jan 2011 | B2 |
7863897 | Slocum, Jr. et al. | Jan 2011 | B2 |
7869854 | Shachar et al. | Jan 2011 | B2 |
7873417 | Demarais et al. | Jan 2011 | B2 |
7887538 | Bleich et al. | Feb 2011 | B2 |
7894905 | Pless et al. | Feb 2011 | B2 |
7896873 | Hiller et al. | Mar 2011 | B2 |
7901400 | Wham et al. | Mar 2011 | B2 |
7901402 | Jones et al. | Mar 2011 | B2 |
7901420 | Dunn | Mar 2011 | B2 |
7905862 | Sampson | Mar 2011 | B2 |
7918850 | Govari et al. | Apr 2011 | B2 |
7927370 | Webler et al. | Apr 2011 | B2 |
7937143 | Demarais et al. | May 2011 | B2 |
7938830 | Saadat et al. | May 2011 | B2 |
7942874 | Eder et al. | May 2011 | B2 |
7942928 | Webler et al. | May 2011 | B2 |
7946976 | Gertner | May 2011 | B2 |
7950397 | Thapliyal et al. | May 2011 | B2 |
7955293 | Nita et al. | Jun 2011 | B2 |
7956613 | Wald | Jun 2011 | B2 |
7959627 | Utley et al. | Jun 2011 | B2 |
7962854 | Vance et al. | Jun 2011 | B2 |
7967782 | Laufer et al. | Jun 2011 | B2 |
7967808 | Fitzgerald et al. | Jun 2011 | B2 |
7972327 | Eberl et al. | Jul 2011 | B2 |
7972330 | Alejandro et al. | Jul 2011 | B2 |
7983751 | Zdeblick et al. | Jul 2011 | B2 |
8001976 | Gertner | Aug 2011 | B2 |
8007440 | Magnin et al. | Aug 2011 | B2 |
8012147 | Lafontaine | Sep 2011 | B2 |
8019435 | Hastings et al. | Sep 2011 | B2 |
8021362 | Deem et al. | Sep 2011 | B2 |
8021413 | Dierking et al. | Sep 2011 | B2 |
8025661 | Arnold et al. | Sep 2011 | B2 |
8027718 | Spinner et al. | Sep 2011 | B2 |
8031927 | Karl et al. | Oct 2011 | B2 |
8033284 | Porter et al. | Oct 2011 | B2 |
8043673 | Lee et al. | Oct 2011 | B2 |
8048144 | Thistle et al. | Nov 2011 | B2 |
8052636 | Moll et al. | Nov 2011 | B2 |
8052700 | Dunn | Nov 2011 | B2 |
8062289 | Babaev | Nov 2011 | B2 |
8075580 | Makower | Dec 2011 | B2 |
8080006 | Lafontaine et al. | Dec 2011 | B2 |
8088127 | Mayse et al. | Jan 2012 | B2 |
8116883 | Williams et al. | Feb 2012 | B2 |
8119183 | O'Donoghue et al. | Feb 2012 | B2 |
8120518 | Jang et al. | Feb 2012 | B2 |
8123741 | Marrouche et al. | Feb 2012 | B2 |
8128617 | Bencini et al. | Mar 2012 | B2 |
8131371 | Demarals et al. | Mar 2012 | B2 |
8131372 | Levin et al. | Mar 2012 | B2 |
8131382 | Asada | Mar 2012 | B2 |
8137274 | Weng et al. | Mar 2012 | B2 |
8140170 | Rezai et al. | Mar 2012 | B2 |
8143316 | Ueno | Mar 2012 | B2 |
8145316 | Deem et al. | Mar 2012 | B2 |
8145317 | Demarais et al. | Mar 2012 | B2 |
8150518 | Levin et al. | Apr 2012 | B2 |
8150519 | Demarais et al. | Apr 2012 | B2 |
8150520 | Demarais et al. | Apr 2012 | B2 |
8152830 | Gumm | Apr 2012 | B2 |
8162933 | Francischelli et al. | Apr 2012 | B2 |
8168275 | Lee et al. | May 2012 | B2 |
8175711 | Demarais et al. | May 2012 | B2 |
8187261 | Watson | May 2012 | B2 |
8190238 | Moll et al. | May 2012 | B2 |
8192053 | Owen et al. | Jun 2012 | B2 |
8198611 | Lafontaine et al. | Jun 2012 | B2 |
8214056 | Hoffer et al. | Jul 2012 | B2 |
8221407 | Phan et al. | Jul 2012 | B2 |
8226637 | Satake | Jul 2012 | B2 |
8231617 | Satake | Jul 2012 | B2 |
8241217 | Chiang et al. | Aug 2012 | B2 |
8257724 | Cromack et al. | Sep 2012 | B2 |
8257725 | Cromack et al. | Sep 2012 | B2 |
8260397 | Ruff et al. | Sep 2012 | B2 |
8263104 | Ho et al. | Sep 2012 | B2 |
8273023 | Razavi | Sep 2012 | B2 |
8277379 | Lau et al. | Oct 2012 | B2 |
8287524 | Siegel | Oct 2012 | B2 |
8287532 | Carroll et al. | Oct 2012 | B2 |
8292881 | Brannan et al. | Oct 2012 | B2 |
8293703 | Averback et al. | Oct 2012 | B2 |
8295902 | Salahieh et al. | Oct 2012 | B2 |
8295912 | Gertner | Oct 2012 | B2 |
8308722 | Ormsby et al. | Nov 2012 | B2 |
8317776 | Ferren et al. | Nov 2012 | B2 |
8317810 | Stangenes et al. | Nov 2012 | B2 |
8329179 | Ni et al. | Dec 2012 | B2 |
8336705 | Okahisa | Dec 2012 | B2 |
8343031 | Gertner | Jan 2013 | B2 |
8343145 | Brannan | Jan 2013 | B2 |
8347891 | Demarais et al. | Jan 2013 | B2 |
8353945 | Andreas et al. | Jan 2013 | B2 |
8364237 | Stone et al. | Jan 2013 | B2 |
8366615 | Razavi | Feb 2013 | B2 |
8382697 | Brenneman et al. | Feb 2013 | B2 |
8388680 | Starksen et al. | Mar 2013 | B2 |
8396548 | Perry et al. | Mar 2013 | B2 |
8398629 | Thistle | Mar 2013 | B2 |
8401667 | Gustus et al. | Mar 2013 | B2 |
8403881 | Ferren et al. | Mar 2013 | B2 |
8406877 | Smith et al. | Mar 2013 | B2 |
8409172 | Moll et al. | Apr 2013 | B2 |
8409193 | Young et al. | Apr 2013 | B2 |
8409195 | Young | Apr 2013 | B2 |
8418362 | Zerfas et al. | Apr 2013 | B2 |
8452988 | Wang | May 2013 | B2 |
8454594 | Demarais et al. | Jun 2013 | B2 |
8460358 | Andreas et al. | Jun 2013 | B2 |
8465452 | Kassab | Jun 2013 | B2 |
8469919 | Ingle et al. | Jun 2013 | B2 |
8473067 | Hastings et al. | Jun 2013 | B2 |
8480663 | Ingle et al. | Jul 2013 | B2 |
8485992 | Griffin et al. | Jul 2013 | B2 |
8486060 | Kotmel et al. | Jul 2013 | B2 |
8486063 | Werneth et al. | Jul 2013 | B2 |
8488591 | Miali et al. | Jul 2013 | B2 |
20010007070 | Stewart et al. | Jul 2001 | A1 |
20010039419 | Francischelli et al. | Nov 2001 | A1 |
20020022864 | Mahvi et al. | Feb 2002 | A1 |
20020042639 | Murphy-Chutorian et al. | Apr 2002 | A1 |
20020045811 | Kittrell et al. | Apr 2002 | A1 |
20020045890 | Celliers et al. | Apr 2002 | A1 |
20020062146 | Makower et al. | May 2002 | A1 |
20020065542 | Lax et al. | May 2002 | A1 |
20020082634 | Kammerer | Jun 2002 | A1 |
20020087151 | Mody et al. | Jul 2002 | A1 |
20020095197 | Lardo et al. | Jul 2002 | A1 |
20020107536 | Hussein | Aug 2002 | A1 |
20020147480 | Mamayek | Oct 2002 | A1 |
20020169444 | Mest et al. | Nov 2002 | A1 |
20020198520 | Coen et al. | Dec 2002 | A1 |
20030050635 | Truckai et al. | Mar 2003 | A1 |
20030065317 | Rudie et al. | Apr 2003 | A1 |
20030092995 | Thompson | May 2003 | A1 |
20030139689 | Shturman et al. | Jul 2003 | A1 |
20030195501 | Sherman et al. | Oct 2003 | A1 |
20030199747 | Michlitsch et al. | Oct 2003 | A1 |
20030229340 | Sherry et al. | Dec 2003 | A1 |
20030233099 | Danaek et al. | Dec 2003 | A1 |
20040010118 | Zerhusen et al. | Jan 2004 | A1 |
20040019348 | Stevens et al. | Jan 2004 | A1 |
20040024371 | Plicchi et al. | Feb 2004 | A1 |
20040043030 | Griffiths et al. | Mar 2004 | A1 |
20040064090 | Keren et al. | Apr 2004 | A1 |
20040073206 | Foley et al. | Apr 2004 | A1 |
20040088002 | Boyle et al. | May 2004 | A1 |
20040093055 | Bartorelli et al. | May 2004 | A1 |
20040106871 | Hunyor et al. | Jun 2004 | A1 |
20040117032 | Roth | Jun 2004 | A1 |
20040147915 | Hasebe | Jul 2004 | A1 |
20040162554 | Lee | Aug 2004 | A1 |
20040162555 | Farley et al. | Aug 2004 | A1 |
20040167506 | Chen | Aug 2004 | A1 |
20040186356 | O'Malley et al. | Sep 2004 | A1 |
20040187875 | He et al. | Sep 2004 | A1 |
20040193211 | Voegele et al. | Sep 2004 | A1 |
20040220556 | Cooper et al. | Nov 2004 | A1 |
20040243022 | Carney et al. | Dec 2004 | A1 |
20040253304 | Gross et al. | Dec 2004 | A1 |
20040267250 | Yon et al. | Dec 2004 | A1 |
20050010095 | Stewart et al. | Jan 2005 | A1 |
20050015125 | Mioduski et al. | Jan 2005 | A1 |
20050080374 | Esch et al. | Apr 2005 | A1 |
20050085841 | Eversull | Apr 2005 | A1 |
20050096647 | Steinke et al. | May 2005 | A1 |
20050129616 | Salcedo et al. | Jun 2005 | A1 |
20050137180 | Robinson et al. | Jun 2005 | A1 |
20050143817 | Hunter et al. | Jun 2005 | A1 |
20050148842 | Wang et al. | Jul 2005 | A1 |
20050149069 | Bertolero et al. | Jul 2005 | A1 |
20050149080 | Hunter et al. | Jul 2005 | A1 |
20050149158 | Hunter et al. | Jul 2005 | A1 |
20050149173 | Hunter et al. | Jul 2005 | A1 |
20050149175 | Hunter et al. | Jul 2005 | A1 |
20050154277 | Tang et al. | Jul 2005 | A1 |
20050154445 | Hunter et al. | Jul 2005 | A1 |
20050154453 | Hunter et al. | Jul 2005 | A1 |
20050154454 | Hunter et al. | Jul 2005 | A1 |
20050165389 | Swain et al. | Jul 2005 | A1 |
20050165391 | Maguire et al. | Jul 2005 | A1 |
20050165467 | Hunter et al. | Jul 2005 | A1 |
20050165488 | Hunter et al. | Jul 2005 | A1 |
20050175661 | Hunter et al. | Aug 2005 | A1 |
20050175662 | Hunter et al. | Aug 2005 | A1 |
20050175663 | Hunter et al. | Aug 2005 | A1 |
20050177103 | Hunter et al. | Aug 2005 | A1 |
20050177225 | Hunter et al. | Aug 2005 | A1 |
20050181004 | Hunter et al. | Aug 2005 | A1 |
20050181008 | Hunter et al. | Aug 2005 | A1 |
20050181011 | Hunter et al. | Aug 2005 | A1 |
20050181977 | Hunter et al. | Aug 2005 | A1 |
20050182479 | Bonsignore et al. | Aug 2005 | A1 |
20050183728 | Hunter et al. | Aug 2005 | A1 |
20050186242 | Hunter et al. | Aug 2005 | A1 |
20050186243 | Hunter et al. | Aug 2005 | A1 |
20050191331 | Hunter et al. | Sep 2005 | A1 |
20050203410 | Jenkins | Sep 2005 | A1 |
20050209587 | Joye et al. | Sep 2005 | A1 |
20050214205 | Salcedo et al. | Sep 2005 | A1 |
20050214207 | Salcedo et al. | Sep 2005 | A1 |
20050214208 | Salcedo et al. | Sep 2005 | A1 |
20050214209 | Salcedo et al. | Sep 2005 | A1 |
20050214210 | Salcedo et al. | Sep 2005 | A1 |
20050214268 | Cavanagh et al. | Sep 2005 | A1 |
20050228286 | Messerly et al. | Oct 2005 | A1 |
20050228415 | Gertner | Oct 2005 | A1 |
20050228460 | Levin et al. | Oct 2005 | A1 |
20050232921 | Rosen et al. | Oct 2005 | A1 |
20050234312 | Suzuki et al. | Oct 2005 | A1 |
20050245862 | Seward | Nov 2005 | A1 |
20050251116 | Steinke et al. | Nov 2005 | A1 |
20050252553 | Ginggen | Nov 2005 | A1 |
20050256398 | Hastings et al. | Nov 2005 | A1 |
20050267556 | Shuros et al. | Dec 2005 | A1 |
20050273149 | Tran et al. | Dec 2005 | A1 |
20060004323 | Chang et al. | Jan 2006 | A1 |
20060018949 | Ammon et al. | Jan 2006 | A1 |
20060024564 | Manclaw | Feb 2006 | A1 |
20060025765 | Landman et al. | Feb 2006 | A1 |
20060062786 | Salcedo et al. | Mar 2006 | A1 |
20060083194 | Dhrimaj et al. | Apr 2006 | A1 |
20060085054 | Zikorus et al. | Apr 2006 | A1 |
20060089637 | Werneth et al. | Apr 2006 | A1 |
20060089638 | Carmel et al. | Apr 2006 | A1 |
20060095096 | DeBenedictis et al. | May 2006 | A1 |
20060106375 | Werneth et al. | May 2006 | A1 |
20060142790 | Gertner | Jun 2006 | A1 |
20060147492 | Hunter et al. | Jul 2006 | A1 |
20060167106 | Zhang et al. | Jul 2006 | A1 |
20060167498 | DiLorenzo | Jul 2006 | A1 |
20060171895 | Bucay-Couto | Aug 2006 | A1 |
20060182873 | Klisch et al. | Aug 2006 | A1 |
20060184221 | Stewart et al. | Aug 2006 | A1 |
20060189896 | Davis | Aug 2006 | A1 |
20060195139 | Gertner | Aug 2006 | A1 |
20060206150 | Demarais et al. | Sep 2006 | A1 |
20060224153 | Fischell et al. | Oct 2006 | A1 |
20060239921 | Mangat et al. | Oct 2006 | A1 |
20060240070 | Cromack et al. | Oct 2006 | A1 |
20060247266 | Yamada et al. | Nov 2006 | A1 |
20060247760 | Ganesan et al. | Nov 2006 | A1 |
20060263393 | Demopulos et al. | Nov 2006 | A1 |
20060269555 | Salcedo et al. | Nov 2006 | A1 |
20060271111 | Demarais et al. | Nov 2006 | A1 |
20060287644 | Inganas et al. | Dec 2006 | A1 |
20070016184 | Cropper et al. | Jan 2007 | A1 |
20070016274 | Boveja et al. | Jan 2007 | A1 |
20070027390 | Maschke et al. | Feb 2007 | A1 |
20070043077 | Mewshaw et al. | Feb 2007 | A1 |
20070043409 | Brian et al. | Feb 2007 | A1 |
20070049924 | Rahn | Mar 2007 | A1 |
20070066972 | Ormsby et al. | Mar 2007 | A1 |
20070067883 | Sretavan | Mar 2007 | A1 |
20070073151 | Lee | Mar 2007 | A1 |
20070093710 | Maschke | Apr 2007 | A1 |
20070100405 | Thompson et al. | May 2007 | A1 |
20070106247 | Burnett et al. | May 2007 | A1 |
20070112327 | Yun et al. | May 2007 | A1 |
20070118107 | Francischelli et al. | May 2007 | A1 |
20070129720 | Demarais et al. | Jun 2007 | A1 |
20070129760 | Demarais et al. | Jun 2007 | A1 |
20070129761 | Demarais et al. | Jun 2007 | A1 |
20070135875 | Demarais et al. | Jun 2007 | A1 |
20070149963 | Matsukuma et al. | Jun 2007 | A1 |
20070162109 | Davila et al. | Jul 2007 | A1 |
20070173805 | Weinberg et al. | Jul 2007 | A1 |
20070179496 | Swoyer et al. | Aug 2007 | A1 |
20070203480 | Mody et al. | Aug 2007 | A1 |
20070207186 | Scanlon et al. | Sep 2007 | A1 |
20070208134 | Hunter et al. | Sep 2007 | A1 |
20070208210 | Gelfand et al. | Sep 2007 | A1 |
20070208256 | Marilla | Sep 2007 | A1 |
20070208301 | Evard et al. | Sep 2007 | A1 |
20070219576 | Cangialosi | Sep 2007 | A1 |
20070225781 | Saadat et al. | Sep 2007 | A1 |
20070233170 | Gertner | Oct 2007 | A1 |
20070239062 | Chopra et al. | Oct 2007 | A1 |
20070248639 | Demopulos et al. | Oct 2007 | A1 |
20070249703 | Mewshaw et al. | Oct 2007 | A1 |
20070254833 | Hunter et al. | Nov 2007 | A1 |
20070265687 | Deem et al. | Nov 2007 | A1 |
20070278103 | Hoerr et al. | Dec 2007 | A1 |
20070282302 | Wachsman et al. | Dec 2007 | A1 |
20070292411 | Salcedo et al. | Dec 2007 | A1 |
20070293782 | Marino | Dec 2007 | A1 |
20070299043 | Hunter et al. | Dec 2007 | A1 |
20080004673 | Rossing et al. | Jan 2008 | A1 |
20080009927 | Vilims | Jan 2008 | A1 |
20080015501 | Gertner | Jan 2008 | A1 |
20080021408 | Jacobsen et al. | Jan 2008 | A1 |
20080033049 | Mewshaw | Feb 2008 | A1 |
20080039746 | Hissong et al. | Feb 2008 | A1 |
20080039830 | Munger et al. | Feb 2008 | A1 |
20080051454 | Wang | Feb 2008 | A1 |
20080064957 | Spence | Mar 2008 | A1 |
20080071269 | Hilario et al. | Mar 2008 | A1 |
20080071306 | Gertner | Mar 2008 | A1 |
20080082093 | Prakash | Apr 2008 | A1 |
20080082109 | Moll et al. | Apr 2008 | A1 |
20080086072 | Bonutti et al. | Apr 2008 | A1 |
20080091193 | Kauphusman et al. | Apr 2008 | A1 |
20080097251 | Babaev | Apr 2008 | A1 |
20080097426 | Root et al. | Apr 2008 | A1 |
20080108867 | Zhou | May 2008 | A1 |
20080119879 | Brenneman et al. | May 2008 | A1 |
20080125772 | Stone et al. | May 2008 | A1 |
20080132450 | Lee et al. | Jun 2008 | A1 |
20080140002 | Ramzipoor et al. | Jun 2008 | A1 |
20080147002 | Gertner | Jun 2008 | A1 |
20080161662 | Golijanin et al. | Jul 2008 | A1 |
20080161717 | Gertner | Jul 2008 | A1 |
20080161801 | Steinke et al. | Jul 2008 | A1 |
20080171974 | Lafontaine et al. | Jul 2008 | A1 |
20080172035 | Starksen et al. | Jul 2008 | A1 |
20080172104 | Kieval et al. | Jul 2008 | A1 |
20080188912 | Stone et al. | Aug 2008 | A1 |
20080188913 | Stone et al. | Aug 2008 | A1 |
20080208162 | Joshi | Aug 2008 | A1 |
20080208169 | Boyle et al. | Aug 2008 | A1 |
20080213331 | Gelfand et al. | Sep 2008 | A1 |
20080215117 | Gross | Sep 2008 | A1 |
20080221448 | Khuri-Yakub et al. | Sep 2008 | A1 |
20080234790 | Bayer et al. | Sep 2008 | A1 |
20080243091 | Humphreys et al. | Oct 2008 | A1 |
20080245371 | Gruber | Oct 2008 | A1 |
20080249525 | Lee et al. | Oct 2008 | A1 |
20080249547 | Dunn | Oct 2008 | A1 |
20080255550 | Bell | Oct 2008 | A1 |
20080255642 | Zarins et al. | Oct 2008 | A1 |
20080262489 | Steinke | Oct 2008 | A1 |
20080275484 | Gertner | Nov 2008 | A1 |
20080281312 | Werneth et al. | Nov 2008 | A1 |
20080281347 | Gertner | Nov 2008 | A1 |
20080287918 | Rosenman et al. | Nov 2008 | A1 |
20080294037 | Richter | Nov 2008 | A1 |
20080300618 | Gertner | Dec 2008 | A1 |
20080312644 | Fourkas et al. | Dec 2008 | A1 |
20080312673 | Viswanathan et al. | Dec 2008 | A1 |
20080317818 | Griffith et al. | Dec 2008 | A1 |
20090018486 | Goren et al. | Jan 2009 | A1 |
20090018609 | DiLorenzo | Jan 2009 | A1 |
20090024194 | Arcot-Krishnamurthy et al. | Jan 2009 | A1 |
20090030312 | Hadjicostis | Jan 2009 | A1 |
20090036948 | Levin et al. | Feb 2009 | A1 |
20090043372 | Northrop et al. | Feb 2009 | A1 |
20090054082 | Kim et al. | Feb 2009 | A1 |
20090062873 | Wu et al. | Mar 2009 | A1 |
20090069671 | Anderson | Mar 2009 | A1 |
20090076409 | Wu et al. | Mar 2009 | A1 |
20090088735 | Abboud et al. | Apr 2009 | A1 |
20090105631 | Kieval | Apr 2009 | A1 |
20090112202 | Young | Apr 2009 | A1 |
20090118620 | Tgavalekos et al. | May 2009 | A1 |
20090118726 | Auth et al. | May 2009 | A1 |
20090125099 | Weber et al. | May 2009 | A1 |
20090131798 | Minar et al. | May 2009 | A1 |
20090143640 | Saadat et al. | Jun 2009 | A1 |
20090156988 | Ferren et al. | Jun 2009 | A1 |
20090157057 | Ferren et al. | Jun 2009 | A1 |
20090157161 | Desai et al. | Jun 2009 | A1 |
20090171333 | Hon | Jul 2009 | A1 |
20090192558 | Whitehurst et al. | Jul 2009 | A1 |
20090198223 | Thilwind et al. | Aug 2009 | A1 |
20090203962 | Miller et al. | Aug 2009 | A1 |
20090203993 | Mangat et al. | Aug 2009 | A1 |
20090204170 | Hastings et al. | Aug 2009 | A1 |
20090210953 | Moyer et al. | Aug 2009 | A1 |
20090216317 | Cromack et al. | Aug 2009 | A1 |
20090221955 | Babaev | Sep 2009 | A1 |
20090226429 | Salcedo et al. | Sep 2009 | A1 |
20090240249 | Chan et al. | Sep 2009 | A1 |
20090247933 | Maor et al. | Oct 2009 | A1 |
20090247966 | Gunn et al. | Oct 2009 | A1 |
20090248012 | Maor et al. | Oct 2009 | A1 |
20090253974 | Rahme | Oct 2009 | A1 |
20090264755 | Chen et al. | Oct 2009 | A1 |
20090270850 | Zhou et al. | Oct 2009 | A1 |
20090281533 | Ingle et al. | Nov 2009 | A1 |
20090287137 | Crowley | Nov 2009 | A1 |
20090318749 | Stolen et al. | Dec 2009 | A1 |
20100009267 | Chase et al. | Jan 2010 | A1 |
20100030061 | Canfield et al. | Feb 2010 | A1 |
20100048983 | Ball et al. | Feb 2010 | A1 |
20100049099 | Thapliyal et al. | Feb 2010 | A1 |
20100049186 | Ingle et al. | Feb 2010 | A1 |
20100049188 | Nelson et al. | Feb 2010 | A1 |
20100049191 | Habib et al. | Feb 2010 | A1 |
20100049283 | Johnson | Feb 2010 | A1 |
20100069837 | Rassat et al. | Mar 2010 | A1 |
20100076299 | Gustus et al. | Mar 2010 | A1 |
20100076425 | Carroux | Mar 2010 | A1 |
20100087782 | Ghaffari et al. | Apr 2010 | A1 |
20100106005 | Karczmar et al. | Apr 2010 | A1 |
20100114244 | Manda et al. | May 2010 | A1 |
20100130836 | Malchano et al. | May 2010 | A1 |
20100137860 | Demarais et al. | Jun 2010 | A1 |
20100137952 | Demarais et al. | Jun 2010 | A1 |
20100160903 | Krespi | Jun 2010 | A1 |
20100160906 | Jarrard | Jun 2010 | A1 |
20100168624 | Sliwa | Jul 2010 | A1 |
20100168731 | Wu et al. | Jul 2010 | A1 |
20100168739 | Wu et al. | Jul 2010 | A1 |
20100174282 | Demarais et al. | Jul 2010 | A1 |
20100191112 | Demarais et al. | Jul 2010 | A1 |
20100191232 | Boveda | Jul 2010 | A1 |
20100204560 | Salahieh | Aug 2010 | A1 |
20100217162 | Hissong et al. | Aug 2010 | A1 |
20100222786 | Kassab | Sep 2010 | A1 |
20100222851 | Deem et al. | Sep 2010 | A1 |
20100222854 | Demarais et al. | Sep 2010 | A1 |
20100228122 | Keenan et al. | Sep 2010 | A1 |
20100249604 | Hastings et al. | Sep 2010 | A1 |
20100249773 | Clark et al. | Sep 2010 | A1 |
20100256616 | Katoh et al. | Oct 2010 | A1 |
20100268217 | Habib | Oct 2010 | A1 |
20100268307 | Demarais et al. | Oct 2010 | A1 |
20100284927 | Lu et al. | Nov 2010 | A1 |
20100286684 | Hata et al. | Nov 2010 | A1 |
20100298821 | Garbagnati | Nov 2010 | A1 |
20100305036 | Barnes et al. | Dec 2010 | A1 |
20100312141 | Keast et al. | Dec 2010 | A1 |
20100324472 | Wulfman | Dec 2010 | A1 |
20110009750 | Taylor et al. | Jan 2011 | A1 |
20110021976 | Li et al. | Jan 2011 | A1 |
20110034832 | Cioanta et al. | Feb 2011 | A1 |
20110040324 | McCarthy et al. | Feb 2011 | A1 |
20110044942 | Puri et al. | Feb 2011 | A1 |
20110060324 | Wu et al. | Mar 2011 | A1 |
20110071400 | Hastings et al. | Mar 2011 | A1 |
20110071401 | Hastings et al. | Mar 2011 | A1 |
20110077498 | McDaniel | Mar 2011 | A1 |
20110092781 | Gertner | Apr 2011 | A1 |
20110092880 | Gertner | Apr 2011 | A1 |
20110104061 | Seward | May 2011 | A1 |
20110112400 | Emery et al. | May 2011 | A1 |
20110118600 | Gertner | May 2011 | A1 |
20110118726 | De La Rama et al. | May 2011 | A1 |
20110130708 | Perry et al. | Jun 2011 | A1 |
20110137155 | Weber et al. | Jun 2011 | A1 |
20110144479 | Hastings et al. | Jun 2011 | A1 |
20110146673 | Keast et al. | Jun 2011 | A1 |
20110166499 | Demarais et al. | Jul 2011 | A1 |
20110178570 | Demarais | Jul 2011 | A1 |
20110200171 | Beetel et al. | Aug 2011 | A1 |
20110202098 | Demarais et al. | Aug 2011 | A1 |
20110207758 | Sobotka et al. | Aug 2011 | A1 |
20110208096 | Demarais et al. | Aug 2011 | A1 |
20110257523 | Hastings et al. | Oct 2011 | A1 |
20110257564 | Demarais et al. | Oct 2011 | A1 |
20110257622 | Salahieh et al. | Oct 2011 | A1 |
20110257641 | Hastings et al. | Oct 2011 | A1 |
20110257642 | Griggs, III | Oct 2011 | A1 |
20110263921 | Vrba et al. | Oct 2011 | A1 |
20110264011 | Wu et al. | Oct 2011 | A1 |
20110264075 | Leung et al. | Oct 2011 | A1 |
20110264086 | Ingle | Oct 2011 | A1 |
20110264116 | Kocur et al. | Oct 2011 | A1 |
20110270238 | Rizq et al. | Nov 2011 | A1 |
20110284693 | Barnard | Nov 2011 | A1 |
20110306851 | Wang | Dec 2011 | A1 |
20110319809 | Smith | Dec 2011 | A1 |
20120029496 | Smith | Feb 2012 | A1 |
20120029500 | Jenson | Feb 2012 | A1 |
20120029505 | Jenson | Feb 2012 | A1 |
20120029509 | Smith | Feb 2012 | A1 |
20120029510 | Haverkost | Feb 2012 | A1 |
20120029511 | Smith et al. | Feb 2012 | A1 |
20120029512 | Willard et al. | Feb 2012 | A1 |
20120029513 | Smith et al. | Feb 2012 | A1 |
20120059241 | Hastings et al. | Mar 2012 | A1 |
20120059286 | Hastings et al. | Mar 2012 | A1 |
20120065506 | Smith | Mar 2012 | A1 |
20120065554 | Pikus | Mar 2012 | A1 |
20120095461 | Herscher et al. | Apr 2012 | A1 |
20120101413 | Beetel et al. | Apr 2012 | A1 |
20120101490 | Smith | Apr 2012 | A1 |
20120101538 | Ballakur et al. | Apr 2012 | A1 |
20120109021 | Hastings et al. | May 2012 | A1 |
20120116382 | Ku et al. | May 2012 | A1 |
20120116383 | Mauch et al. | May 2012 | A1 |
20120116392 | Willard | May 2012 | A1 |
20120116438 | Salahieh et al. | May 2012 | A1 |
20120116486 | Naga et al. | May 2012 | A1 |
20120123243 | Hastings | May 2012 | A1 |
20120123258 | Willard | May 2012 | A1 |
20120123261 | Jenson et al. | May 2012 | A1 |
20120123303 | Sogard et al. | May 2012 | A1 |
20120123406 | Edmunds et al. | May 2012 | A1 |
20120130289 | Demarais et al. | May 2012 | A1 |
20120130345 | Levin et al. | May 2012 | A1 |
20120130359 | Turovskiy | May 2012 | A1 |
20120130360 | Buckley et al. | May 2012 | A1 |
20120130362 | Hastings et al. | May 2012 | A1 |
20120130368 | Jenson | May 2012 | A1 |
20120130458 | Ryba et al. | May 2012 | A1 |
20120136344 | Buckley et al. | May 2012 | A1 |
20120136349 | Hastings | May 2012 | A1 |
20120136350 | Goshgarian et al. | May 2012 | A1 |
20120136417 | Buckley et al. | May 2012 | A1 |
20120136418 | Buckley et al. | May 2012 | A1 |
20120143181 | Demarais et al. | Jun 2012 | A1 |
20120143293 | Mauch et al. | Jun 2012 | A1 |
20120143294 | Clark et al. | Jun 2012 | A1 |
20120150267 | Buckley et al. | Jun 2012 | A1 |
20120157986 | Stone et al. | Jun 2012 | A1 |
20120157987 | Steinke et al. | Jun 2012 | A1 |
20120157988 | Stone et al. | Jun 2012 | A1 |
20120157989 | Stone et al. | Jun 2012 | A1 |
20120157992 | Smith et al. | Jun 2012 | A1 |
20120157993 | Jenson et al. | Jun 2012 | A1 |
20120158101 | Stone et al. | Jun 2012 | A1 |
20120158104 | Huynh et al. | Jun 2012 | A1 |
20120172837 | Demarais et al. | Jul 2012 | A1 |
20120172870 | Jenson et al. | Jul 2012 | A1 |
20120184952 | Jenson et al. | Jul 2012 | A1 |
20120197198 | Demarais et al. | Aug 2012 | A1 |
20120197252 | Deem et al. | Aug 2012 | A1 |
20120232409 | Stahmann et al. | Sep 2012 | A1 |
20120259269 | Meyer | Oct 2012 | A1 |
20120265066 | Crow et al. | Oct 2012 | A1 |
20120265198 | Crow et al. | Oct 2012 | A1 |
20130012844 | Demarais et al. | Jan 2013 | A1 |
20130012866 | Deem et al. | Jan 2013 | A1 |
20130012867 | Demarais et al. | Jan 2013 | A1 |
20130013024 | Levin et al. | Jan 2013 | A1 |
20130023865 | Steinke et al. | Jan 2013 | A1 |
20130035681 | Subramaniam et al. | Feb 2013 | A1 |
20130066316 | Steinke et al. | Mar 2013 | A1 |
20130085489 | Fain et al. | Apr 2013 | A1 |
20130090563 | Weber | Apr 2013 | A1 |
20130090578 | Smith et al. | Apr 2013 | A1 |
20130090647 | Smith | Apr 2013 | A1 |
20130090649 | Smith et al. | Apr 2013 | A1 |
20130090650 | Jenson et al. | Apr 2013 | A1 |
20130090651 | Smith | Apr 2013 | A1 |
20130090652 | Jenson | Apr 2013 | A1 |
20130096550 | Hill | Apr 2013 | A1 |
20130096553 | Hill et al. | Apr 2013 | A1 |
20130096554 | Groff et al. | Apr 2013 | A1 |
20130096604 | Hanson et al. | Apr 2013 | A1 |
20130110106 | Richardson | May 2013 | A1 |
20130116687 | Willard | May 2013 | A1 |
20130165764 | Scheuermann et al. | Jun 2013 | A1 |
20130165844 | Shuros et al. | Jun 2013 | A1 |
20130165916 | Mathur et al. | Jun 2013 | A1 |
20130165917 | Mathur et al. | Jun 2013 | A1 |
20130165920 | Weber et al. | Jun 2013 | A1 |
20130165923 | Mathur et al. | Jun 2013 | A1 |
20130165924 | Mathur et al. | Jun 2013 | A1 |
20130165925 | Mathur et al. | Jun 2013 | A1 |
20130165926 | Mathur et al. | Jun 2013 | A1 |
20130165990 | Mathur et al. | Jun 2013 | A1 |
20130172815 | Perry et al. | Jul 2013 | A1 |
20130172872 | Subramaniam et al. | Jul 2013 | A1 |
20130172877 | Subramaniam et al. | Jul 2013 | A1 |
20130172878 | Smith | Jul 2013 | A1 |
20130172879 | Sutermeister | Jul 2013 | A1 |
20130172880 | Willard | Jul 2013 | A1 |
20130172881 | Hill et al. | Jul 2013 | A1 |
20130304062 | Chan | Nov 2013 | A1 |
20140074083 | Horn et al. | Mar 2014 | A1 |
Number | Date | Country |
---|---|---|
10038737 | Feb 2002 | DE |
1053720 | Nov 2000 | EP |
1180004 | Feb 2002 | EP |
1335677 | Aug 2003 | EP |
1874211 | Jan 2008 | EP |
1906853 | Apr 2008 | EP |
1961394 | Aug 2008 | EP |
1620156 | Jul 2009 | EP |
2076193 | Jul 2009 | EP |
2091455 | Aug 2009 | EP |
2197533 | Jun 2010 | EP |
2208506 | Jul 2010 | EP |
1579889 | Aug 2010 | EP |
2092957 | Jan 2011 | EP |
2349044 | Aug 2011 | EP |
2027882 | Oct 2011 | EP |
2378956 | Oct 2011 | EP |
2037840 | Dec 2011 | EP |
2204134 | Apr 2012 | EP |
2320821 | Oct 2012 | EP |
2456301 | Jul 2009 | GB |
9501751 | Jan 1995 | WO |
9858588 | Dec 1998 | WO |
9900060 | Jan 1999 | WO |
9935986 | Jul 1999 | WO |
0047118 | Aug 2000 | WO |
0066021 | Nov 2000 | WO |
0195820 | Dec 2001 | WO |
03026525 | Apr 2003 | WO |
2004100813 | Nov 2004 | WO |
2004110258 | Dec 2004 | WO |
2005041810 | May 2005 | WO |
2006105121 | Oct 2006 | WO |
2008014465 | Jan 2008 | WO |
2008049087 | Apr 2008 | WO |
2008061152 | May 2008 | WO |
2009121017 | Oct 2009 | WO |
2010067360 | Jun 2010 | WO |
2010102310 | Sep 2010 | WO |
2010132703 | Nov 2010 | WO |
2011005901 | Jan 2011 | WO |
2011053757 | May 2011 | WO |
2011053772 | May 2011 | WO |
2011091069 | Jul 2011 | WO |
2011130534 | Oct 2011 | WO |
2011143468 | Nov 2011 | WO |
2012019156 | Feb 2012 | WO |
2013049601 | Apr 2013 | WO |
2013096913 | Jun 2013 | WO |
2013096922 | Jun 2013 | WO |
Entry |
---|
US 8,398,630, 03/2013, Demarais et al. (withdrawn) |
CardioVascular Technologies Inc., “Heated Balloon Device Technology,” 11 pages, 2008. |
Strategic Business Development, Inc., “Thermal and Disruptive Angioplasty: A Physician's Guide,” 8 pages, 1990. |
Zhang et al., “Non-contact Radio-Frequency Ablation for Obtaining Deeper Lesions,” IEEE Transaction on Biomedical Engineering, vol. 50, No. 2, 6 pages, Feb. 2003. |
Lazebnik et al., “Tissue Strain Analytics Virtual Touch Tissue Imaging and Qualification,” Siemens Whitepaper, Oct. 2008, 7 pages. |
Han et al., “Third-Generation Cryosurgery for Primary and Recurrent Prostate Caner,” BJU International, vol. 93, pp. 14-18, 2004. |
Zhou et al., “Mechanism Research of Cryoanalgesia,” Forefront Publishing Group, 1995. |
Florete, “Cryoblative Procedure for Back Pain,” Jacksonville Medicine, Oct. 1998, 10 pages. |
Stevenson, “Irrigated RF Ablation: Power Titration and Fluid Management for Optimal Safety Efficacy,” 2005, 4 pages. |
Giliatt et al., “The Cause of Nerve Damage in Acute Compression,” Trans Am Neurol Assoc, 1974: 99; 71-4. |
Omura et al., “A Mild Acute Compression Induces Neurapraxia in Rat Sciatic Nerve,” The International Journal of Neuroscience, vol. 114 (12), pp. 1561-1572, Dec. 2004. |
Baun, “Interaction with Soft Tissue,” Principles of General & Vascular Sonography, Chapter 2, pp. 23-24, Before Mar. 2012. |
Blue Cross Blue Shield Medical Policy, “Surgery Section—MRI-Guided Focused Ultrasound (MRgFUS) for the Treatment of Uterine Fibroids and Other Tumors,” 2005, 5 pages. |
Gentry et al., “Combines 3D Intracardiac Echo and Ultrasound Ablation,” Medical Imaging 2003: Ultrasonic and Signal Processing, vol. 5035, 2003, pp. 166-173. |
Lafon et al., “Optmizing the Shape of Ultrasound Transducers for Interstitial Thermal Ablations,” MEd Phys. Mar. 2002; 29(3): 290-7 (abstract only). |
G. Ter Haar, “Ultrasound Focal Beam Surgery,” Ultrasound in Med. & Biol., 1995, vol. 21, No. 9, pp. 1089-1100. |
Seip et al., “Transurethral High Intensity Focused Ultrasound: Catheter Based Prototypes and Experimental Results,” IEEE Ultrasonics Symposium Proceeding, 2000, 4 pages. |
Toytman et al., “Tissue Dissection with Ultrafast Laser Using Extended and Multiple Foci,” SPIE Proceeding, Optical Interactions with Tissues and Cells XXI, vol. 7562, 2010, 10 pages. |
Zhou et al., “Non-Thermal Ablation of Rabbit Liver VX2 Tumore by Pulsed High Intensity Focused Ultrasound Contrast Agent: Pathological Characteristics,” World Journal of Gastroenterology, vol. 14(43), Nov. 21, 2008, pp. 6743-6747. |
Van Den Berg, “Light echoes image the human body,” OLE, Oct. 2001, p. 35-37. |
“IntraLuminal: Products,” IntraLuminal Therapeutics, Inc., 2003, p. 1-9. |
“Laser Catheter to Aid Coronary Surgery,” TechTalk: MIT, Jan. 9, 1991, p. 1-4. |
“Optical Coherence Tomography: LightLab Imaging Starts US Cardiology Clinical Investigations,” LightLab Imaging Technology, 2002. |
“Optical Coherence Tomography: LightLab Sees Bright Prospects for Cardiac Application of OCT Technology,” LightLab Imaging Technology, 2001, vol. 27, No. 35. |
“Products—Functional Measurement,” VOLCANO Functional Measurement Products US, Mar. 24, 2003, p. 1-2. |
Brown et al., “Radiofrequency capacitive heaters: the effect of coupling medium resistivity on power absorption along a mouse leg,” Physics in Medicine and Biology, 1993, p. 1-12, vol. 38. |
Carrington, “Future of CVI: It's all about plaque: Identification of vulnerable lesions, not ‘rusty pipes,’ could become of cornerstone preventive cardiology,” Diagnostic Imaging, 2001, p. 1-8. |
Chen et al., “Percutaneous pulmonary artery denervation completely abolishes experimental pulmonary arterial hypertension in vivo,” EuroIntervention, 2013, p. 1-8. |
Cimino, “Preventing plaque attack,” Mass High Tech, 2001, p. 1-2. |
Dahm et al., “Relation of Degree of Laser Debulking of In-Stent Restenosis as a Predictor of Restenosis Rate,” The American Journal of Cardiology, 2002, p. 68-70, vol. 90. |
De Korte et al., “Characterization of Plaque Components With Intravascular Ultrasound Elastography in Human Femoral and Coronary Arteries In Vitro,” Circulation, Aug. 8, 2000, p. 617-623. |
Durney et al., “Radiofrequency Radiation Dosimetry Handbook,” Oct. 1986, p. 1-2, Fourth Edition. |
Durney et al., “Radiofrequency Radiation Dosimetry Handbook: Contents,” Oct. 1986, p. 1-5, Fourth Edition. |
Fournier-Desseux et al., “Assessment of 1-lead and 2-lead electrode patterns in electrical impedance endotomography,” Physiological Measurement, 2005, p. 337-349. Vo. 26, Institute of Physics Publishing. |
Fram et al., “Feasibility of Radiofrequency Powered, Thermal Balloon Ablation of Atrioventricular Bypass Tracts via the Coronary Sinus: In Vivo Canine Studies,” PACE, Aug. 1995, p. 1518-1530, vol. 18. |
Fram et al., “Low Pressure Radiofrequency Balloon Angioplasty: Evaluation in Porcine Peripheral Arteries,” JACC, 1993, p. 1512-1521, vol. 21, No. 6, American College of Cardiology. |
Fujimori et al., “Significant Prevention of In-Stent Restenosis by Evans Blue in Patients with Acute Myocardial Infarction,” American Heart Association, 2002. |
Fujita et al., “Sarpogrelate, An Antagonist of 5-HT(2A) Receptor, Treatment Reduces Restenosis After Coronary Stenting,” American Heart Association, 2002. |
Gabriel, “Appendix A: Experimental Data,” 1999, p. 1-21. |
Gabriel, “Appendix C: Modeling the frequency dependence of the dielectric properties to a 4 dispersions spectrum,” p. 1-49, Nov. 6, 1997. |
Gregory et al., “Liquid Core Light Guide for Laser Angioplasty,” The Journal of Quantum Electronics, Dec. 1990, p. 2289-2296, vol. 26, No. 12. |
Kaplan et al., “Healing after Arterial Dilatation with Radiofrequency Thermal and Nonthermal Balloon Angioplasty Sytems,” Journal of Investigative Surgery, 1993, p. 33-52, vol. 6. |
Kolata, “New Studies Question Value of Opening Arteries,” The New York Times, Mar. 21, 2004, p. 1-5. |
Konings et al., “Development of an Intravascular Impedance Catheter for Detection of Fatty Lesions in Arteries,” IEEE Transactions on Medical Imaging, Aug. 1997, p. 439-446, vol. 16, No. 4. |
Kurtz et al., “Lamellar Refractive Surgery with Scanned Intrastromal Picosecond and Femtosecond Laser Pulses in Animal Eyes,” Journal of Refractive Surgery, Sep./Oct. 1998, p. 541-548. |
Lee et al., “Thermal Compression and Molding of Atherosclerotic Vascular Tissue With Use of Radiofrequency Energy: Implications for Radiofrequency Balloon Angioplasty,” JACC, 1989, p. 1167-1175, vol. 13, No. 5, American College of Cardiology. |
Lima et al., “Efficacy and Safety of Oral Sirolimus to Treat and Prevent In-Stent Restenosis: A Pilot Study Results,” American Heart Association, 2002, p. 2929. |
Lima et al., “Systemic Immunosuppression Inhibits In-Stent Coronary Intimal Proliferation in Renal Transplant Patients,” American Heart Association, 2002, p. 2928. |
Morice et al., “A Randomized Comparison of a Sirolimus-Eluting Stent With a Standard Stent for Coronary Revascularization,” The New England Journal of Medicine, Jun. 6, 2012, p. 1773-1780, vol. 346, No. 23. |
Muller-Leisse et al., “Effectiveness and Safety of Ultrasonic Atherosclerotic Plaque Ablation: In Vitro Investigation,” CardioVascular and Interventional Radiology, 1993, p. 303-307, vol. 16. |
Nair et al., “Regularized Autoregressive Analysis of Intravascular Ultrasound Backscatter: Improvement in Spatial Accuracy of Tissue Maps,” IEEE Transactions on Ultrasonics, Apr. 2004, p. 420-431, vol. 51, No. 4. |
Popma et al., “Percutaneous Coronary and Valvular Intervention,” Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th edition, p. 1364-1405, 2005. |
Resar et al., “Endoluminal Sealing of Vascular Wall Disruptions With Radiofrequency-Heated Balloon Angioplasty,” Catheterization and Cardiovascular Diagnosis, 1993, p. 161-167, vol. 29. |
Romer et al., “Histopathology of Human Coronary Atherosclerosis by Quantifying Its Chemical Composition With Raman Spectroscopy,” Circulation, 1998, p. 878-885, vol. 97. |
Schauerte et al., “Catheter Ablation of Cardiac Autonomic Nerves for Prevention of Vagal Atrial Fibrillation,” Circulation, 2000, p. 2774-2780, vol. 102. |
Scheller et al., “Intracoronary Paclitaxel Added to Contrast Media Inhibits In-Stent Restenosis of Porcine Coronary Arteries,” American Heart Association, 2002, p. 2227. |
Scheller et al., “Potential solutions to the current problem: coated balloon,” EuroIntervention, 2008, p. C63-C66, vol. 4 (Supplement C). |
Shaffer, “Scientific basis of laser energy,” Clinics in Sports Medicine, 2002, p. 585-598, vol. 21. |
Shmatukha et al., “MRI temperature mapping during thermal balloon angioplasty,” Physics in Medicine and Biology, 2006, p. N163-N171, vol. 51. |
Slager et al., “Vaporization of Atherosclerotic Plaques by Spark Erosion,” J Am Coll Cardiol, 1985, p. 21-25. |
Stiles et al., “Simulated Characterization of Atherosclerotic Lesions in the Coronary Arteries by Measurement of Bioimpedance,” IEEE Transactions on Biomedical Engineering, Jul. 2003, p. 916-921, vol. 50, No. 7. |
Suselbeck et al., “In vivo intravascular electric impedance spectroscopy using a new catheter with integrated microelectrodes,” Basic Res Cardiol, 2005, p. 28-34, vol. 100. |
Suselbeck et al., “Intravascular electric impedance spectroscopy of atherosclerotic lesions using a new impedance catheter system,” Basic Res Cardiol, 2005, p. 446-452, vol. 100. |
Tepe et al., “Local Delivery of Paclitaxel to Inhibit Restenosis during Angioplasty of the Leg,” The New England Journal of Medicine, 2008, p. 689-699, vol. 358. |
“Optical Coherence Tomography: Advantages of OCT,” LightLab Imaging Technology, printed Sep. 3, 2003. |
“Optical Coherence Tomography: Image Gallery Cardiovascular Procedures,” LightLab Imaging Technology, printed Sep. 3, 2003. |
“Optical Coherence Tomography: What is OCT?,” LightLab Imaging Technology, printed Sep. 3, 2003. |
“Optical Coherence Tomography: Why Use OCT?,” LightLab Imaging Technology, printed Sep. 3, 2003. |
Pieper et al. “Design and implementation of a new computerized system for intraoperative cardiac mapping”, J. Appl. Physiol. 71(4): 1529-1539, 1991. |
Number | Date | Country | |
---|---|---|---|
20140276789 A1 | Sep 2014 | US |
Number | Date | Country | |
---|---|---|---|
61798352 | Mar 2013 | US | |
61919582 | Dec 2013 | US |